



**Dose-Response Effects of Exercise Training on the
Subjective Sleep Quality of Postmenopausal Women: A
Randomised Controlled Trial**

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001044
Article Type:	Research
Date Submitted by the Author:	21-Feb-2012
Complete List of Authors:	Kline, Christopher; University of Pittsburgh School of Medicine, Department of Psychiatry Sui, Xuemi; University of South Carolina, Exercise Science Hall, Martica; University of Pittsburgh School of Medicine, Department of Psychiatry Youngstedt, Shawn; University of South Carolina, Department of Exercise Science Blair, Steven; Univ South Carolina, Dept of Exercise Science Earnest, Conrad; Louisiana State University, Department of Preventive Medicine Church, Timothy; Louisiana State University, Department of Preventive Medicine
Primary Subject Heading:	Public health
Secondary Subject Heading:	Sports and exercise medicine, Mental health
Keywords:	sleep, exercise, postmenopausal, exercise training

SCHOLARONE™
Manuscripts

1
2
3 **Dose-Response Effects of Exercise Training on the Subjective Sleep Quality of**
4
5 **Postmenopausal Women: A Randomised Controlled Trial**
6
7
8
9

10 Christopher E. Kline,¹ Xuemei Sui,² Martica Hall,¹ Shawn D. Youngstedt,^{2,3,4}

11
12 Steven N. Blair,^{2,5} Conrad P. Earnest,⁶ Timothy S. Church⁶
13
14
15
16

17 ¹ *Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA USA;*

18 ² *Department of Exercise Science, University of South Carolina, Columbia, SC USA;*

19 ³ *WJB Dorn VA Medical Center, Columbia, SC USA;*

20 ⁴ *Department of Psychology, University of South Carolina, Columbia, SC USA;*

21 ⁵ *Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC*

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
USA;

⁶ *Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State
University, Baton Rouge, LA USA.*

Corresponding Author: Christopher E. Kline, Ph.D., Department of Psychiatry, University of
Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213; tel.: 412-578-
9554; fax: 412-246-5300; e-mail: klinec@upmc.edu.

Key words: exercise, sleep, postmenopausal, exercise training

Main text word count: 3729

ABSTRACT

Objective: To investigate whether a dose-response relationship existed between exercise and subjective sleep quality in postmenopausal women.

Design: Parallel group randomised controlled trial.

Setting: Clinical exercise physiology laboratory in Dallas, Texas.

Participants: 437 sedentary overweight/obese postmenopausal women with baseline sleep data (out of 464 enrolled for participation).

Intervention: Participants were randomised to 1 of 4 treatments, each of 6 months' duration: a non-exercise control treatment ($n=92$) or one of three dosages of moderate-intensity exercise (50% of VO_{2peak}), designed to meet 50% ($n=151$), 100% ($n=99$), or 150% ($n=95$) of NIH Consensus Development Panel physical activity recommendations. Exercise dosages were structured to elicit energy expenditures of 4, 8 or 12 kilocalories per kilogram of body weight per week (KKW), respectively. Analyses were intent-to-treat.

Primary outcome measures: Continuous scores and odds of having significant sleep disturbance, as assessed by the Sleep Problems Index from the 6-item Medical Outcomes Study (MOS) Sleep Scale. Outcome assessors were blinded to participant randomisation assignment.

Results: Change in the MOS Sleep Problems Index score significantly differed by treatment group (control: -2.09 [95% confidence interval, -4.58 to 0.40], 4 KKW: -3.93 [-5.87 to -1.99], 8 KKW: -4.06 [-6.45 to -1.67], 12 KKW: -6.22 [-8.68 to -3.77]; $P=.04$), with a significant dose-response trend observed ($P=.02$). Exercise training participants had lower odds of having significant sleep disturbance at post-intervention compared to control (4 KKW OR: 0.37 [0.19 to 0.73], 8 KKW: 0.36 [0.17 to 0.77], 12 KKW: 0.34 [0.16 to 0.72]). The magnitude of weight loss

1
2
3 did not differ between treatment conditions. Improvements in sleep quality were not related to
4
5 changes in body weight, resting parasympathetic control, or cardiorespiratory fitness.
6
7

8 **Conclusion:** Exercise training induced significant improvement in subjective sleep quality in
9
10 postmenopausal women, with even a low dose of exercise resulting in greatly reduced odds of
11
12 having significant sleep disturbance.
13

14
15 **Trial registration:** clinicaltrials.gov identifier: NCT00011193.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article Focus:

- Sleep disturbance is prevalent in postmenopausal women, with 35-60% reporting significant sleep problems.
- Effective, safe and easily available treatment options for disturbed sleep in postmenopausal women are lacking.
- There has been equivocal evidence as to whether exercise improves sleep in postmenopausal women, though possible dose-response effects have been noted.

Key Messages:

- Exercise resulted in significant improvement in subjective sleep quality in postmenopausal women, with reduced odds of having sleep disturbance at post-intervention with even 50% of the recommended dose of exercise for adults.
- The effects of exercise on sleep quality were independent of changes in body weight, resting parasympathetic control, or cardiorespiratory fitness.

Strengths and Limitations:

- The study constitutes the largest randomised controlled trial on exercise and sleep quality, using a structured dose of exercise and a validated measure of sleep quality.
- Only self-reported sleep was assessed; objective measurement of sleep, with either actigraphy or polysomnography, was not conducted.
- Despite the high prevalence of sleep disturbance in the sample, participants were not selected on the basis of sleep complaints.

INTRODUCTION

Disturbed sleep is a common complaint among women, with increasing prevalence beginning at the menopausal transition. Postmenopausal women are more likely to report sleep problems than premenopausal or perimenopausal women,[1] with 35-60% of postmenopausal women reporting significant sleep problems.[2] The first-line treatment options for sleep complaints, hypnotic medication and cognitive behavioral therapy, have associated concerns about the safety of long-term use or treatment availability, respectively.[3,4] Furthermore, results are conflicting on the effect of hormone replacement therapy (HRT) on sleep quality,[5,6] despite the effectiveness of HRT at reducing other menopausal symptoms.

A nonpharmacological treatment that has been traditionally thought to improve sleep is exercise. In epidemiologic research, exercise has frequently been associated with better sleep.[7] However, experimental research has provided less compelling evidence,[8] particularly when regarding postmenopausal women. Of the four randomised trials that have investigated the effect of exercise on sleep quality in this population,[9-12] only one reported a significant improvement in subjective sleep quality following an exercise intervention.[12] However, despite the generally negative findings from these studies involving postmenopausal women, possible dose-response effects of exercise on sleep quality were noted. In one of these studies, women who performed at least 225 minutes of morning exercise per week had less trouble falling asleep compared to those who exercised less than 180 minutes per week in the morning.[9] Likewise, another study reported a positive association between walking frequency and improvements in sleep.[11]

To our knowledge, no research has directly investigated the effects of different doses of exercise on sleep quality. The Dose-Response to Exercise in postmenopausal Women (DREW) trial was conducted to investigate the health effects of 50%, 100%, and 150% of the NIH

1
2
3 Consensus Development Panel physical activity recommendations in a group of sedentary
4
5 postmenopausal women.[13] Results on the primary outcomes of the study, cardiorespiratory
6
7 fitness and blood pressure, have already been reported.[14] Subjective sleep quality was also
8
9 assessed in this trial as an exploratory outcome, and the data provided herein provides the first
10
11 systematic examination of whether a dose-response relationship exists between exercise and
12
13 subjective sleep quality. It was hypothesised that, in comparison to a non-exercise control group,
14
15 subjective sleep quality would improve with increasing dosage of exercise.
16
17
18

19 20 METHODS

21
22 A complete description of the recruitment and screening procedures has been published
23
24 elsewhere.[13] Briefly, the study was a randomised, controlled, multi-arm parallel group trial in
25
26 which the primary outcomes were examining whether there were dose-response effects on
27
28 cardiorespiratory fitness and blood pressure with incrementally increasing doses of energy
29
30 expenditure.[13,14] The study was approved annually by the Cooper Institute Institutional
31
32 Review Board, and written informed consent was obtained by all participants prior to study
33
34 involvement.
35
36
37

38 39 Participants

40
41 Participants were recruited from the Dallas, Texas, metropolitan area from April 2001 to
42
43 June 2005. Of 4545 women screened for eligibility, those who were aged 45-75 years,
44
45 postmenopausal, sedentary (≤ 20 min of exercise on ≤ 2 days/week and < 8000 steps/day,
46
47 averaged over one week), overweight or obese (body mass index [BMI] of 25-43 kg/m²), and
48
49 had normal to mildly elevated resting blood pressure (systolic blood pressure [SBP] of 120-159
50
51 mm Hg and diastolic blood pressure [DBP] ≤ 99 mm Hg) were eligible to participate (Figure 1).
52
53 Exclusion criteria included significant cardiovascular disease, recent hospitalisation for mental
54
55
56
57
58
59
60

1
2
3 illness or significant symptoms of depression (score ≥ 10 on the Center for Epidemiologic
4
5 Studies Depression scale), or any other health condition that would contraindicate participation
6
7
8 in an exercise program. Overall, 464 women were randomised to treatment, with baseline sleep
9
10 data available for 437 participants.

11 12 **Randomisation and Retention**

13
14
15 Prior to randomisation, participants completed a two-week run-in period, in which
16
17 participants received lifestyle modification instruction over the course of six laboratory visits.
18
19 The primary purpose of this run-in period was to maximise retention and adherence to the
20
21 subsequent intervention. Participants were compensated for completing baseline and post-
22
23 intervention assessments, with additional compensation based on intervention adherence.[13]
24
25

26
27 Allocation of participants to treatment conditions was accomplished using a computer-
28
29 generated randomisation sequence, determined from randomly permuted blocks of equal length
30
31 with fixed numbers of treatment allotments to balance treatment enrollments over time.

32
33 Allocation concealment was achieved by placing treatment assignment letters into sequentially
34
35 numbered opaque envelopes sealed by the study statistician. At the time of randomisation,
36
37 envelopes were opened by a staff member not affiliated with the randomisation process.[13]
38
39

40
41 Participants were randomised to one of four treatment conditions: a non-exercise control
42
43 group, or one of three exercise groups expending 4, 8, or 12 kilocalories per kilogram of body
44
45 weight per week (KKW). Energy expenditure levels for the exercise groups were designed to
46
47 correspond with 50%, 100%, and 150% of the NIH Consensus Development Panel physical
48
49 activity recommendations, respectively.[15]
50
51

52 **Interventions**

53
54
55
56
57
58
59
60

1
2
3 Women assigned to the exercise groups participated in 3-4 training sessions/week for 6
4 months, alternating between semirecumbent cycle ergometer and treadmill exercise. Training
5 sessions were conducted in a supervised laboratory setting, and exercise dosage was closely
6 monitored for each session. Training intensity was moderate, set at the heart rate associated with
7 50% of each woman's VO_{2peak} and continuously monitored by heart rate telemetry. To determine
8 the number of calories that needed to be expended each week, participants were weighed weekly
9 and their weight was multiplied by the exercise dosage.
10
11
12
13
14
15
16
17
18

19
20 Exercise dose was gradually increased to minimise injury risk. All exercise training
21 groups expended 4 KKW during the first intervention week, with the 4-KKW group continuing
22 at that dose for 6 months. The 8- and 12-KKW groups increased their energy expenditure by 1
23 KKW until they reached their appointed exercise doses.
24
25
26
27
28

29 **Blinding**

30
31 Although participants could not be blinded to their treatment, staff were separated into
32 intervention and assessment teams to ensure blinding of all assessment staff to participant
33 randomisation assignment. Participants were consistently reminded to refrain from discussing
34 their randomisation assignments with outcome assessment staff.
35
36
37
38
39
40

41 **Sleep Measure**

42
43 Subjective sleep quality was assessed with six items from the Medical Outcomes Study
44 (MOS) Sleep Scale.[16] At baseline and post-intervention, participants were asked to respond
45 based on their sleep during the previous four weeks. One question, which addressed the length of
46 time to fall asleep, was framed with five response options ranging from 0-15 minutes to > 60
47 minutes. For the remaining five questions (i.e., restless sleep, daytime drowsiness, difficulty
48 falling asleep, awakening from sleep and experiencing difficulty returning to sleep, staying
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 awake during the day), participants were asked to respond on a 5-point scale, ranging from “none
4 of the time” to “all of the time”. Item responses were assigned scores using conventional scoring
5 rules, with higher scores indicating a greater severity of sleep disturbance. A modified Sleep
6 Problems Index (SPI), utilising all six sleep items, provided a measure of overall sleep
7 quality.[17] SPI scores greater than 25 were considered to indicate significant sleep disturbance,
8 as prior work utilising a 9-item SPI reported that a cutpoint of > 25 identified individuals who
9 considered themselves to have a sleep problem with a sensitivity of 86.2% and specificity of
10 66.3%.[17]

11
12 Scores on the MOS Sleep Scale have been shown to correlate with other MOS health
13 items,[16] differentiate between those with and without chronic health conditions,[17] and
14 improve with treatment of chronic health conditions.[18] Normative values for the general
15 population have also been developed.[17]

31 **Other Measures**

32
33 Baseline demographic and health characteristics were assessed by completion of a
34 comprehensive medical history questionnaire. Height and weight were measured with a
35 calibrated stadiometer and electronic scale, respectively. Diet was assessed before and following
36 the intervention using a semi-quantitative food frequency questionnaire, whereas unsupervised
37 physical activity was monitored throughout the study with a pedometer (Accusplit Eagle, Japan).

38
39 Cardiorespiratory fitness (VO_{2peak}) was assessed from maximal exercise testing using a
40 cycle ergometer (Excalibur Sport, Lode Medical Technology, Groningen, Netherlands), as
41 previously described.[14] Testing was performed twice at baseline and twice at post-
42 intervention, with values from each timepoint averaged. Heart rate variability (HRV) was
43 measured from the final 5 min of a 25-min resting assessment, as previously described.[19] The
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 square root of the mean of the sum of the squares of differences between adjacent R-R intervals
4
5 (rMSSD), a marker of parasympathetic activity,[20] was retained for analysis.
6
7

8 **Statistical Power**

9
10 Sample size was originally based on having adequate power to detect changes in the
11 primary outcomes of the overall study, VO_{2peak} and blood pressure.[14] Additional participants
12 were allocated to the 4 KKW condition to increase statistical power for detecting smaller
13 anticipated fitness gains in this group. Because sleep was not a primary outcome in the design of
14 the original study, there was no opportunity before data collection to investigate sample size or
15 power for this outcome variable. Nevertheless, given the current enrollment, the study had 84%
16 power (assuming two-tailed $\alpha = 0.05$) to detect an effect size of 0.20 for MOS SPI score
17 reduction.
18
19
20
21
22
23
24
25
26
27
28

29 **Statistical Analysis**

30
31 Baseline sleep quality was compared against normative data[17] using a one-sample *t*-
32 test. Continuous MOS SPI values were examined across quartiles of BMI, parasympathetic tone
33 (rMSSD), and cardiorespiratory fitness (VO_{2peak}) with analysis of covariance (ANCOVA),
34 controlling for age, BMI, sleep medication use, and HRT use. The likelihood of having
35 significant sleep disturbance at baseline (i.e., MOS SPI > 25) was evaluated with logistic
36 regression across the same quartiles using the same covariates.
37
38
39
40
41
42
43
44
45

46 Two primary outcomes were evaluated for the current study: (1) change in continuous
47 MOS SPI score across treatment groups; (2) odds of having significant sleep disturbance at post-
48 intervention across treatment groups. Change in continuous MOS SPI scores across groups was
49 tested by ANCOVA, with adjustment for age, BMI, sleep medication use, HRT use, and baseline
50 MOS SPI values. Individual treatment groups were compared to the control group with Tukey-
51
52
53
54
55
56
57
58
59
60

1
2
3 Kramer adjustment for multiple comparisons. An α level of .05 was used because it was our *a*
4 *priori* intention to compare only the separate treatment groups with the control group. Dose-
5
6 *priori* intention to compare only the separate treatment groups with the control group. Dose-
7
8 response trends were analysed using least-squares regression of MOS SPI change across groups.
9
10 Logistic regression examined the odds of having significant sleep disturbance at post-
11
12 intervention, following adjustment for age, BMI, sleep medication and HRT use, and baseline
13
14 sleep disturbance ($SPI > 25$, $SPI \leq 25$). Unadjusted analyses provided similar results to those
15
16 with covariate control, so only those results with full covariate adjustment were reported.
17
18

19
20 Finally, to examine whether improved sleep quality was significantly influenced by body
21
22 weight, parasympathetic tone, or cardiorespiratory fitness, changes in weight, rMSSD, and
23
24 VO_{2peak} were added to the ANCOVA and logistic regression analyses. Additionally, among
25
26 completed participants, changes in MOS SPI score were evaluated across quartiles of change in
27
28 body weight, rMSSD, and VO_{2peak} following adjustment for age, treatment, BMI, sleep
29
30 medication use, HRT use, and baseline MOS SPI score.
31
32

33
34 Analyses were limited to participants with baseline MOS Sleep data. Primary analyses
35
36 were conducted using the intent-to-treat principle; if post-intervention data were missing,
37
38 baseline values were carried forward for analysis. When analyses were restricted to only those
39
40 participants with baseline and post-intervention MOS Sleep data ($n = 359$), results were not
41
42 substantively changed; therefore, only intent-to-treat analyses were presented. All analyses were
43
44 performed using SAS version 9.2 (SAS Institute, Cary, NC). All tests were two-tailed, with
45
46 statistical significance set at $P \leq .05$.
47
48
49

50 RESULTS

51 Participant Characteristics

52
53
54
55
56
57
58
59
60

1
2
3 A summary of participant characteristics is provided in Table 1. Mean age and BMI of
4
5 the 437 participants were 57.3 ± 6.5 yr and 31.8 ± 3.9 kg/m², respectively.
6
7

8 Baseline MOS SPI values and prevalence of sleep disturbance are provided in Table 1.
9
10 Of the 437 participants, 46% of the sample ($n = 200$) were considered to have significant sleep
11
12 disturbance at baseline, as defined as MOS SPI > 25. Baseline sleep quality of the participants
13
14 was significantly worse than normative values[17] (normative value: 25.79; $t_{436} = 2.42$, $P = .02$),
15
16 a magnitude of 0.12 SD.[21]
17
18

19 Baseline continuous MOS SPI values and odds of sleep disturbance across quartiles of
20
21 BMI, rMSSD, and VO_{2peak} are shown in Table 2. Sleep quality significantly differed among
22
23 quartiles of rMSSD ($F_{3,343} = 2.55$, $P = .05$), with the lowest quartile of rMSSD having
24
25 significantly worse baseline sleep quality than the other quartiles of rMSSD. Similarly, each
26
27 quartile of rMSSD was associated with lower odds of having significant sleep disturbance at
28
29 baseline compared to the lowest quartile of rMSSD. No differences in MOS SPI values or odds
30
31 of having significant sleep disturbance were observed across quartiles of BMI or VO_{2peak}.
32
33
34
35

36 **Exercise Training Adherence, Diet and Unsupervised Activity**

37
38 Treatment adherence was calculated as the percentage of exercise energy expenditure
39
40 achieved compared to the amount of exercise energy expenditure that was prescribed. Adherence
41
42 was similar between exercise groups (4 KKW: $95.1 \pm 16.1\%$, 8 KKW: $88.5 \pm 26.1\%$, 12 KKW:
43
44 $92.5 \pm 20.9\%$), as previously reported.[14]
45
46
47

48 Changes in diet and unsupervised activity have been previously reported.[14,22] Pre- to
49
50 post-intervention changes in energy intake did not differ between treatment conditions.
51
52 Pedometer-assessed unsupervised activity ranged from 4766 to 5067 steps/day at baseline and
53
54 did not differ between groups. Compared to baseline, daily steps increased for each group at
55
56
57
58
59
60

1
2
3 month 1 (each $P < .05$), with greater steps in the control group than the three exercise groups
4
5 (each $P < .05$). However, no differences in daily steps between the control and exercise groups
6
7 were observed by months 5 and 6. Among the exercise groups, daily steps did not change from
8
9 months 1 through 6. Therefore, the results reported here are unlikely to be due to changes in diet
10
11 or spontaneous activity outside the exercise training laboratory.
12
13

14 15 **Changes in Sleep Quality with Exercise Training**

16
17 Changes in sleep quality with exercise training are depicted in Figure 2. A significant
18
19 effect of the intervention was noted in the full model ($F_{8,428} = 17.35, P < .001$), with treatment
20
21 group being an independent predictor of change in continuous MOS SPI score ($F_{3,428} = 2.79, P =$
22
23 $.04$) following control for age, BMI, HRT use, sleep medication use, and baseline MOS SPI
24
25 values. Moreover, a significant linear dose-response effect was found for MOS SPI scores across
26
27 treatment groups ($P = .02$). When compared against control, a significantly greater improvement
28
29 in MOS SPI score was found for the 12-KKW group ($P = .02$).
30
31
32
33

34 The association between sleep disturbance (i.e., MOS SPI > 25) at post-intervention and
35
36 treatment is summarised in Table 3. Compared to control and following covariate adjustment,
37
38 each exercise training group had lower odds of having significant sleep disturbance following the
39
40 intervention, with the odds of having significant sleep disturbance decreasing while exercise
41
42 dose increased (linear trend $P = .01$).
43
44
45

46 47 **Influences of Change in Weight, Fitness, and Parasympathetic Tone on Sleep**

48
49 Post-intervention changes in body weight, parasympathetic tone, and cardiorespiratory
50
51 fitness for the overall DREW sample have been previously reported.[14,19] In the present
52
53 study's sample, the magnitude of weight loss did not differ between treatment groups (control: -
54
55 1.08 [3.70], 4 KKW: -1.23 [3.43], 8 KKW: -1.60 [3.23], 12 KKW: -1.25 [2.83] kg; $F_{3,433} = 0.43,$
56
57
58
59
60

1
2
3 $P = .73$). Cardiorespiratory fitness improved with exercise training in a dose-dependent manner
4
5 (control: -0.20 [1.88], 4 KKW: 0.59 [1.83], 8 KKW: 1.13 [1.54], 12 KKW: 1.42 [1.79]

6
7 mL/kg/min; $F_{3,433} = 15.32$, $P < .001$). Among those with usable HRV and sleep data ($n = 351$),
8
9 rMSSD improved in a dose-dependent fashion with exercise training (control: 0.20 [8.45], 4
10
11 KKW: 2.72 [9.20], 8 KKW: 3.72 [11.47], 12 KKW: 5.29 [9.51] ms; $F_{3,347} = 3.82$, $P = .01$).

12
13
14 When added to the model analysing differences in continuous MOS SPI change among treatment
15
16 groups, none of these covariates were significant ($P \leq .14$), and inclusion of these variables did
17
18 not alter the previously noted treatment group differences or linear dose-response effects. When
19
20 individually added to logistic regression analyses, none of these covariates significantly affected
21
22 the odds of having significant sleep disturbance at post-intervention (Table 3). In addition, when
23
24 change in MOS SPI was evaluated across quartiles of change in body weight, rMSSD, or
25
26 VO_{2peak} , no significant-between group differences were noted (data not shown). Finally, change
27
28 in MOS SPI did not correlate with change in body weight, rMSSD or VO_{2peak} ($r < .03$, $P > .58$).

33 34 **DISCUSSION**

35
36 The key finding from exploratory analyses of the DREW randomised controlled trial was
37
38 that exercise training significantly improved subjective sleep quality in overweight/obese
39
40 postmenopausal women. Specifically, we observed a dose-response trend for the continuous
41
42 MOS SPI values and, perhaps most notably, significantly reduced odds of having sleep
43
44 disturbance at post-intervention with even 50% of the recommended dose of exercise for adults.
45
46 Interestingly, the improvements in sleep quality were not related to changes in body weight,
47
48 parasympathetic tone, or cardiorespiratory fitness.
49
50

51 52 **Previous research**

1
2
3 Previous research with postmenopausal women had yielded conflicting findings
4 regarding whether exercise improved sleep.[9-12] While suggested by prior studies in this
5 population,[9,11] the present study is the first to document a dose-response relationship between
6 exercise and improved subjective sleep quality. Although sleep was an exploratory outcome of
7 the DREW study, it is the largest clinical trial to date that has examined the relationship between
8 aerobic exercise dose and sleep quality. Our current findings mirror the overall body of research
9 indicating that exercise improves sleep, most prominently in those with existing sleep
10 disturbances.[8]
11
12
13
14
15
16
17
18
19
20
21

22 **Clinical implications**

23
24 When considering the improvements in continuous MOS SPI scores following exercise
25 training, the clinical significance is uncertain. The observation that only those who exercised at a
26 12-KKW dose experienced a significant improvement in sleep quality compared to control may
27 be viewed as discouraging, as this dose equated to approximately 190 min/wk of moderate-
28 intensity aerobic exercise[14] and many individuals may not be willing to perform that much
29 exercise to improve sleep. However, the significant dose-response effect suggests that any dose
30 of exercise should benefit sleep, albeit with larger effects noted with higher levels of energy
31 expenditure.
32
33
34
35
36
37
38
39
40
41
42

43 In contrast, the greatly reduced odds of having significant sleep disturbance following
44 exercise training suggests that exercise may hold the most promise as a treatment option for
45 postmenopausal women with significant sleep disturbance. In particular, even an exercise dose
46 consisting of 50% of the NIH Consensus Panel physical activity recommendations significantly
47 reduced the odds of having a post-intervention MOS SPI > 25. This is noteworthy, since sleep
48 complaints are prevalent in postmenopausal women[1] and current treatment options, such as
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 HRT and hypnotic medication, have often been found to be only mildly efficacious at improving
4 sleep quality compared to placebo in postmenopausal women.[6,23]
5
6

7
8 The mechanisms by which exercise may improve subjective sleep quality in
9
10 postmenopausal women are unknown. Although the present study was not specifically designed
11
12 to address mechanisms of effect, secondary analyses focused on changes in three variables which
13
14 have been shown to be related to sleep: body weight, parasympathetic activity, and
15
16 cardiorespiratory fitness. There is a clear association between obesity and disturbed sleep,[24]
17
18 and weight loss has been found to reduce sleep complaints.[25] Likewise, poor sleepers have
19
20 been found to have impaired sleep HRV,[26] and exercise training has been well-documented to
21
22 improve autonomic function.[27] Finally, physical fitness has been previously associated with
23
24 sleep quality,[28] and greater improvements in fitness have been associated with better sleep
25
26 outcomes in some experimental studies.[9,12]
27
28
29
30

31
32 Nonetheless, in the present study, changes in body weight, parasympathetic tone, or
33
34 cardiorespiratory fitness were not significantly related to changes in sleep, whether assessed by
35
36 covariate control, change in sleep quality across quartiles of change in these variables, or
37
38 correlations between change in these variables and change in sleep quality. Although significant
39
40 improvements were noted for rMSSD and VO_{2peak} following exercise training in this
41
42 sample,[14,19] the variability associated with the sleep measure used in the current study may
43
44 have masked any possible associations. The present study suggests that exercise training can
45
46 result in improved sleep quality independent of weight loss, increased fitness, or improved
47
48 autonomic balance.
49
50
51

52 **Strengths and weaknesses**

53
54
55
56
57
58
59
60

1
2
3 Strengths of the study include a randomised controlled design, closely supervised
4
5 intervention, use of a validated measure of sleep quality, and the largest experimental sample
6
7 size to investigate the effects of exercise on sleep. The study population was another strength, as
8
9 the prevalence of disturbed sleep was high. Finally, assessment of variables that are related to
10
11 sleep quality and may contribute to improved sleep following exercise training was another
12
13 strength of the study.
14
15

16
17 A limitation of the study is that sleep quality was not a primary outcome of the original
18
19 DREW trial. Therefore, results should be interpreted cautiously. Another study limitation is that
20
21 sleep was not objectively assessed (i.e., via wrist actigraphy or polysomnography). Because of
22
23 the subjective nature of the outcome and impossibility of blinding participants to their treatment,
24
25 improvements in self-reported sleep quality may have been subject to expectancy effects, as
26
27 exercise is commonly believed to improve sleep quality.[7] However, the finding of a significant
28
29 linear trend between exercise dose and improvement in sleep quality would not necessarily be
30
31 expected. Moreover, that sleep was not a primary outcome of interest and part of a wide range of
32
33 study assessments further reduces the chance of expectancy or demand biases. Additionally,
34
35 there is growing recognition of the merit of assessing subjective sleep quality.[29] For instance,
36
37 in contrast with subjective sleep quality, objective sleep has not been found to be altered across
38
39 the menopausal transition.[30] Furthermore, impaired subjective sleep quality is what prompts
40
41 search for treatment, and recent evidence suggests that traditional objective sleep measures might
42
43 be inadequate for detecting subtle indicators of disturbed sleep.[31] It is also noteworthy that
44
45 subjective sleep quality has been associated with quality of life and physical and mental health in
46
47 postmenopausal women.[32]
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A lack of assessment of obstructive sleep apnoea (OSA) was another limitation. Although
4
5 OSA is considered to be a male-dominated sleep disorder, postmenopausal OSA prevalence is
6
7 similar between males and females.[33] Moreover, excess weight is the primary cause of OSA
8
9 for most adults,[34] which would place this overweight/obese sample at even higher risk for
10
11 OSA. Evidence suggests that exercise, in the absence of more established treatments or
12
13 significant weight loss, is moderately efficacious at reducing OSA severity and improving
14
15 sleep.[35] However, dose-response effects of exercise on OSA severity are unknown.
16
17
18

19
20 Finally, because aerobic activity was the only mode of exercise studied in the DREW
21
22 trial, the possible effects of resistance exercise on sleep quality could not be examined in this
23
24 sample. Resistance training has been shown to improve sleep quality,[36] though there has been
25
26 minimal work comparing different doses of resistance exercise on sleep quality.[37]
27
28

29 **Conclusions**

30
31 In summary, in a sample of overweight/obese postmenopausal women, exercise training
32
33 significantly reduced the odds of having significant sleep disturbance. These improvements in
34
35 sleep were independent of the effects of exercise training on body weight, parasympathetic tone,
36
37 or cardiorespiratory fitness. Additional research with more comprehensive measurement of sleep
38
39 is warranted, but exercise training appears to significantly improve sleep quality in
40
41 postmenopausal women.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

We thank the DREW participants and the Cooper Institute staff for their efforts on this study.

Contributors: TSC and SNB designed and organised the study. TSC, CPE, and SNB collected the data. CEK and XS performed the statistical analyses. CEK wrote the first draft of the manuscript. XS, MHH, SDY, CPE, SNB, and TSC provided critical input at all stages and critically reviewed and contributed to the final draft. CEK and TSC are guarantors.

Funding: This work was supported by grants HL66262 and T32 HL082610-05 from the National Institutes of Health, and American Heart Association Texas Affiliate award 02651404. Life Fitness (Schiller Park, Illinois) provided exercise equipment for this study.

Competing interest statement: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work (aside from the funding sources listed); no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Institutional Review Boards of the Cooper Institute (Dallas, TX) and the Pennington Biomedical Research Center (Baton Rouge, LA).

Role of the study sponsors: The sponsors had no role in the study design, protocol development, or in conducting the trial, data collection, data analysis, or preparation of the manuscript.

Data sharing: The data set will be available from the corresponding author as part of an academic collaboration.

Trial registration: Clinicaltrials.gov identification number NCT00011193.

REFERENCES

1. Kravitz HM, Ganz PA, Bromberger J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. *Menopause* 2003;10:19-28.
2. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. *Ann Intern Med* 2005;142:1003-13.
3. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. *J Gen Intern Med* 2007;22:1335-50.
4. Nowakowski S, Meliska CJ, Martinez LF, et al. Sleep and menopause. *Curr Neurol Neurosci Rep* 2009;9:165-72.
5. Sarti CD, Chiantera A, Graziottin A, et al. Hormone therapy and sleep quality in women around menopause. *Menopause* 2005;12:545-51.
6. Kalleinen N, Polo O, Himanen SL, et al. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. *Climacteric* 2008;11:233-43.
7. Youngstedt SD, Kline CE. Epidemiology of exercise and sleep. *Sleep Biol Rhythms* 2006;4:215-21.
8. Youngstedt SD. Effects of exercise on sleep. *Clin Sports Med* 2005;24:355-65.
9. Tworoger SS, Yasui Y, Vitiello MV, et al. Effects of a yearlong moderate-intensity exercise and a stretching intervention on sleep quality in postmenopausal women. *Sleep* 2003;26:830-6.
10. Elavsky S, McAuley E. Lack of perceived sleep improvement after 4-month structured exercise programs. *Menopause* 2007;14:535-40.

- 1
2
3 11. Wilbur J, Miller AM, McDevitt J, et al. Menopausal status, moderate-intensity walking, and
4 symptoms in midlife women. *Res Theory Nurs Pract* 2005;19:163-80.
5
6
- 7
8 12. King AC, Oman RF, Brassington GS, et al. Moderate-intensity exercise and self-rated
9 quality of sleep in older adults. A randomized controlled trial. *JAMA* 1997;277:32-7.
10
11
- 12 13. Morss GM, Jordan AN, Skinner JS, et al. Dose Response to Exercise in Women aged 45-75
13 yr (DREW): design and rationale. *Med Sci Sports Exerc* 2004;36:336-44.
14
15
- 16 14. Church TS, Earnest CP, Skinner JS, et al. Effects of different doses of physical activity on
17 cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women
18 with elevated blood pressure: a randomized controlled trial. *JAMA* 2007;297:2081-91.
19
20
- 21 15. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health.
22 Physical activity and cardiovascular health. *JAMA* 1996;276:241-6.
23
24
- 25 16. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, Jr., eds. *Measuring*
26 *Functioning and Well-being: The Medical Outcomes Study Approach*. Durham, NC: Duke
27 University Press 1992:235-59.
28
29
- 30 17. Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the Medical Outcomes
31 Study Sleep measure. *Sleep Med* 2005;6:41-4.
32
33
- 34 18. Allen RP, Kosinski M, Hill-Zabala CE, et al. Psychometric evaluation and tests of validity
35 of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). *Sleep Med* 2009;10:531-
36 9.
37
38
- 39 19. Earnest CP, Lavie CJ, Blair SN, et al. Heart rate variability characteristics in sedentary
40 postmenopausal women following six months of exercise training: the DREW study. *PLoS*
41 *One* 2008;3:e2288.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. *Eur Heart J* 1996;17:354-81.
 21. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Philadelphia, PA: Lawrence Erlbaum Associates, Inc. 1988.
 22. Church TS, Martin CK, Thompson AM, et al. Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women. *PLoS One* 2009;4:e4515.
 23. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. *Obstet Gynecol* 2006;108:1402-10.
 24. Fogelholm M, Kronholm E, Kukkonen-Harjula K, et al. Sleep-related disturbances and physical inactivity are independently associated with obesity in adults. *Int J Obes (Lond)* 2007;31:1713-21.
 25. Dixon JB, Schachter LM, O'Brien PE. Sleep disturbance and obesity: changes following surgically induced weight loss. *Arch Intern Med* 2001;161:102-6.
 26. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. *Psychosom Med*. 1998;60:610-5.
 27. Routledge FS, Campbell TS, Fetridge-Durdle JA, et al. Improvements in heart rate variability with exercise therapy. *Can J Cardiol* 2010;26:303-12.
 28. Lee AJ, Lin WH. Association between sleep quality and physical fitness in female young adults. *J Sports Med Phys Fitness* 2007;47:462-7.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
29. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
30. Young T, Rabago D, Zgierska A, et al. Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. *Sleep* 2003;26:667-72.
31. Perlis ML, Smith MT, Andrews PJ, et al. Beta/Gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. *Sleep* 2001;24:110-7.
32. Baker FC, Wolfson AR, Lee KA. Association of sociodemographic, lifestyle, and health factors with sleep quality and daytime sleepiness in women: findings from the 2007 National Sleep Foundation "Sleep in America Poll". *J Womens Health* 2009;18:841-9.
33. Young T, Finn L, Austin D, et al. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. *Am J Respir Crit Care Med* 2003;167:1181-5.
34. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl Physiol* 2005;99:1592-9.
35. Kline CE, Crowley EP, Ewing GB, et al. The effect of exercise training on obstructive sleep apnea and sleep quality: a randomized controlled trial. *Sleep* 2011;34:1631-40.
36. Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of the effect of exercise on sleep. *Sleep* 1997;20:95-101.
37. Singh NA, Stavrinou TM, Scarbek Y, et al. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. *J Gerontol A Biol Sci Med Sci* 2005;60:768-76.

FIGURE LEGENDS

Figure 1. *Participant screening and study flow.* Of 4545 screened for participation, 464 postmenopausal women were randomised to one of four treatments. Baseline MOS Sleep data were available for 437 participants; those who discontinued the study or without follow-up MOS Sleep data had baseline data carried forward for analysis. BMI: body mass index; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

Figure 2. *Change in MOS Sleep Problems Index scores among treatment groups.* Data presented as least-squares means \pm 95% confidence intervals. Analyses adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and baseline MOS SPI score. * Indicates difference from control ($P = .02$). KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

TABLES

Table 1. Baseline Participant Characteristics.

	All (N=437)	Control (n=92)	Exercise Groups		
			4 KKW (n=151)	8 KKW (n=99)	12 KKW (n=95)
Age, y	57.32 (6.46)	57.14 (5.91)	57.78 (6.53)	57.58 (6.63)	56.47 (6.72)
Education, y	14.03 (2.11)	14.01 (2.12)	13.80 (2.02)	14.37 (2.06)	14.00 (2.28)
Married, No. (%)	398 (91)	86 (93)	141 (94)	87 (88)	84 (88)
Ethnicity/race, No. (%)					
White	278 (64)	58 (63)	92 (61)	60 (61)	68 (72)
African-American	128 (29)	23 (25)	49 (32)	32 (32)	24 (25)
Hispanic/Other	31 (7)	11 (12)	10 (7)	7 (7)	3 (3)
Employed, No. (%)	304 (70)	62 (67)	105 (70)	67 (68)	70 (74)
Cigarette Smoking, No. (%)	25 (6)	5 (5)	8 (5)	4 (4)	8 (8)
Medication Use, No. (%)					
Antihypertensive	126 (29)	22 (24)	41 (27)	32 (32)	31 (33)
Hyperlipidemia	73 (17)	14 (15)	31 (21)	17 (17)	11 (12)
Thyroid	65 (15)	12 (13)	19 (13)	16 (16)	18 (19)
Antidepressant	78 (18)	16 (17)	28 (19)	18 (18)	16 (17)
HRT	202 (46)	48 (52)	67 (44)	43 (43)	44 (46)
Antianxiety	20 (5)	7 (8)	7 (5)	4 (4)	2 (2)
Sedatives/sleep aids	12 (3)	4 (4)	5 (3)	3 (3)	0 (0)
Energy Intake, kcal/d	2277.2 (952.6)	2277.4 (947.9)	2213.1 (941.6)	2290.7 (930.7)	2364.7 (1003.5)
Anthropometrics					
Weight, kg	84.46 (11.82)	85.77 (12.43)	83.56 (11.42)	84.74 (12.43)	84.33 (11.24)
Body mass index, kg/m ²	31.77 (3.85)	32.29 (3.94)	31.54 (3.80)	31.98 (4.08)	31.44 (3.58)
Cardiorespiratory Fitness					
Relative VO _{2peak} , mL/kg/min	15.37 (2.92)	15.56 (3.00)	15.44 (3.00)	14.70 (2.49)	15.77 (3.05)
Absolute VO _{2peak} , L/min	1.29 (0.26)	1.33 (0.28)	1.28 (0.24)	1.24 (0.24)	1.32 (0.26)
Heart Rate Variability [*]					
rMSSD, ms	22.83 (11.56)	23.35 (11.01)	23.58 (12.24)	23.25 (11.29)	20.68 (11.19)
Subjective Sleep Quality					
MOS Sleep Problems Index	27.92 (18.40)	28.37 (19.71)	27.03 (17.92)	27.35 (18.10)	29.47 (18.32)
Sleep disturbance, No. (%)	200 (46)	38 (41)	65 (43)	49 (49)	48 (51)

Data presented as mean (standard deviation) unless otherwise indicated. * Samples for rMSSD

data were 351, 79, 123, 73, and 76 participants for All, Control, 4 KKW, 8 KKW, and 12 KKW groups, respectively. Abbreviations: HRT: hormone replacement therapy; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study; rMSSD: square root of the mean of the sum of the squares of differences between adjacent R-R intervals; VO_{2peak}: peak rate of oxygen consumption.

Table 2. Associations Between Baseline Sleep Quality and BMI, Parasympathetic Tone, and Cardiorespiratory Fitness.

Variable	MOS SPI score (95% CI)	OR of MOS SPI > 25 (95% CI)
BMI (kg/m²)		
Q1: ≥ 34.7	27.95 (24.54, 31.36)	1.00 (referent)
Q2: 31.7 - < 34.7	24.37 (20.92, 27.82)	0.60 (0.35, 1.03)
Q3: 28.6 - < 31.7	30.48 (27.03, 33.94)	1.14 (0.67, 1.96)
Q4: < 28.6	28.85 (25.46, 32.24)	0.98 (0.58, 1.68)
Linear <i>P</i>	.26	.53
rMSSD (ms)		
Q1: < 15.0	31.77 (27.95, 35.59)	1.00 (referent)
Q2: 15.0 - < 20.9	24.77 (21.04, 28.51)*	0.53 (0.29, 0.97)
Q3: 20.9 - < 29.0	25.22 (21.36, 29.09)*	0.43 (0.23, 0.81)
Q4: ≥ 29.0	26.50 (22.64, 30.35)*	0.46 (0.25, 0.86)
Linear <i>P</i>	.08	.01
VO_{2peak} (mL/kg/min)		
Q1: < 13.4	29.55 (25.86, 33.25)	1.00 (referent)
Q2: 13.4 - < 15.2	28.80 (25.35, 32.25)	1.22 (0.70, 2.13)
Q3: 15.2 - < 17.0	28.60 (25.05, 32.15)	1.04 (0.58, 1.87)
Q4: ≥ 17.0	24.91 (21.41, 28.42)	0.63 (0.34, 1.14)
Linear <i>P</i>	.10	.09

Continuous baseline MOS SPI scores (left panels) and odds ratios of having significant sleep disturbance at baseline (MOS SPI > 25) (right panels) across quartiles of baseline BMI, rMSSD, and VO_{2peak}. All analyses adjusted for age, BMI, sleep medication use, and HRT use, except when the covariate quartile was the independent variable. * indicates significant difference ($P \leq .05$) in MOS SPI score compared to quartile 1 (referent group). Abbreviations: BMI: body mass index; CI: confidence interval; MOS: Medical Outcomes Study; Q: quartile; rMSSD: square root of the mean of the sum of the squares of differences between adjacent R-R intervals; SPI: Sleep Problems Index; VO_{2peak}: peak rate of oxygen consumption.

Table 3. Prevalence and Odds of Significant Sleep Disturbance (i.e., MOS SPI > 25) at Post-Intervention.

	Prevalence	Model 1	Model 2	Model 3	Model 4
	<i>n</i> (%)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
Control	41 (45%)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
4 KKW	46 (31%)	0.37 (0.19, 0.73)	0.37 (0.19, 0.73)	0.34 (0.19, 0.73)	0.37 (0.19, 0.73)
8 KKW	33 (33%)	0.36 (0.17, 0.77)	0.36 (0.17, 0.77)	0.32 (0.17, 0.77)	0.36 (0.17, 0.77)
12 KKW	31 (33%)	0.34 (0.16, 0.72)	0.34 (0.16, 0.72)	0.28 (0.16, 0.72)	0.34 (0.16, 0.72)
Linear trend <i>P</i>		.01	.01	.006	.02
Weight change		---	1.00 (0.93, 1.08)	---	---
VO _{2peak} change		---	---	1.10 (0.95, 1.26)	---
rMSSD change		---	---	---	1.01 (0.98, 1.04)

Model 1 adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and

baseline sleep quality (SPI ≤ 25, SPI > 25); Model 2 adjusted for change in body weight in

addition to variables included in Model 1; Model 3 adjusted for change in VO_{2peak} in addition to

variables included in Model 1; Model 4 adjusted for change in rMSSD in addition to variables

included in Model 1. Abbreviations: CI: confidence interval; KKW: kilocalories of energy

expenditure per kilogram of body weight per week; OR: odds ratio; rMSSD: square root of the

mean of the sum of the squares of differences between adjacent R-R intervals; VO_{2peak}: peak rate

of oxygen consumption.




Figure 1. Participant screening and study flow. Of 4545 screened for participation, 464 postmenopausal women were randomised to one of four treatments. Baseline MOS Sleep data were available for 437 participants; those who discontinued the study or without follow-up MOS Sleep data had baseline data carried forward for analysis. BMI: body mass index; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.
215x187mm (279 x 279 DPI)




Figure 2. Change in MOS Sleep Problems Index scores among treatment groups. Data presented as least-squares means \pm 95% confidence intervals. Analyses adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and baseline MOS SPI score. * Indicates difference from control ($P = .02$). KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study. 82x65mm (279 x 279 DPI)



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	p.1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	pp. 2-3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	pp. 5-6
	2b	Specific objectives or hypotheses	p. 6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	p. 6, p. 10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	pp. 6-7
	4b	Settings and locations where the data were collected	p. 6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	pp. 7-8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	pp. 8-10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	p. 10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	p. 7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	p. 7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	p. 7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	p. 7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	p. 8

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	p. 7
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	pp. 10-11
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	pp. 10-11
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment,	
10	diagram is strongly	and were analysed for the primary outcome	p. 12; Fig. 1
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons	Fig. 1
12	Recruitment	14a Dates defining the periods of recruitment and follow-up	p. 6
13		14b Why the trial ended or was stopped	NA
14			
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	p. 12, Table 1
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis	
17		was by original assigned groups	p.11, Fig. 1
18			
19	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	p. 13, Fig. 2, Table
20	estimation	precision (such as 95% confidence interval)	3
21		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	p. 13, Table 3
22	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,	
23		distinguishing pre-specified from exploratory	pp. 13-14
24			
25	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA
26			
27	Discussion		
28	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	pp. 16-18
29	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	p. 15, pp. 17-18
30	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	pp. 14-15
31			
32	Other information		
33	Registration	23 Registration number and name of trial registry	p. 3, p. 20
34	Protocol	24 Where the full trial protocol can be accessed, if available	p. 6, Ref. 13
35	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	pp. 19-20
36			

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.



Dose-Response Effects of Exercise Training on the Subjective Sleep Quality of Postmenopausal Women: Exploratory Analyses of a Randomised Controlled Trial

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001044.R1
Article Type:	Research
Date Submitted by the Author:	27-May-2012
Complete List of Authors:	Kline, Christopher; University of Pittsburgh School of Medicine, Department of Psychiatry Sui, Xuemi; University of South Carolina, Exercise Science Hall, Martica; University of Pittsburgh School of Medicine, Department of Psychiatry Youngstedt, Shawn; University of South Carolina, Department of Exercise Science Blair, Steven; Univ South Carolina, Dept of Exercise Science Earnest, Conrad; University of Bath, Department for Health Church, Timothy; Louisiana State University, Department of Preventive Medicine
Primary Subject Heading:	Public health
Secondary Subject Heading:	Sports and exercise medicine, Mental health
Keywords:	sleep, exercise, postmenopausal, exercise training

SCHOLARONE™
Manuscripts

1
2
3 **Dose-Response Effects of Exercise Training on the Subjective Sleep Quality of**
4
5 **Postmenopausal Women: Exploratory Analyses of a Randomised Controlled Trial**
6
7
8
9

10 Christopher E. Kline,¹ Xuemei Sui,² Martica Hall,¹ Shawn D. Youngstedt,^{2,3,4}

11
12 Steven N. Blair,^{2,5} Conrad P. Earnest,⁶ Timothy S. Church⁷
13
14
15
16

17 ¹ *Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA USA;*

18 ² *Department of Exercise Science, University of South Carolina, Columbia, SC USA;*

19 ³ *WJB Dorn VA Medical Center, Columbia, SC USA;*

20 ⁴ *Department of Psychology, University of South Carolina, Columbia, SC USA;*

21 ⁵ *Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC*

22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
USA;

⁶ *Department for Health, University of Bath, Bath, UK;*

⁷ *Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State
University, Baton Rouge, LA USA.*

Corresponding Author: Christopher E. Kline, Ph.D., Department of Psychiatry, University of

Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213; tel.: 412-578-

9554; fax: 412-246-5300; e-mail: klinec@upmc.edu.

Key words: exercise, sleep, postmenopausal, exercise training

Main text word count: 3755

ABSTRACT

Objective: To investigate whether a dose-response relationship existed between exercise and subjective sleep quality in postmenopausal women. This objective represents a post-hoc assessment which was not previously considered.

Design: Parallel group randomised controlled trial.

Setting: Clinical exercise physiology laboratory in Dallas, Texas.

Participants: 437 sedentary overweight/obese postmenopausal women.

Intervention: Participants were randomised to 1 of 4 treatments, each of 6 months' duration: a non-exercise control treatment ($n=92$) or one of three dosages of moderate-intensity exercise (50% of VO_{2peak}), designed to meet 50% ($n=151$), 100% ($n=99$), or 150% ($n=95$) of NIH Consensus Development Panel physical activity recommendations. Exercise dosages were structured to elicit energy expenditures of 4, 8 or 12 kilocalories per kilogram of body weight per week (KKW), respectively. Analyses were intent-to-treat.

Primary outcome measures: Continuous scores and odds of having significant sleep disturbance, as assessed by the Sleep Problems Index from the 6-item Medical Outcomes Study (MOS) Sleep Scale. Outcome assessors were blinded to participant randomisation assignment.

Results: Change in the MOS Sleep Problems Index score significantly differed by treatment group (control: -2.09 [95% confidence interval, -4.58 to 0.40], 4 KKW: -3.93 [-5.87 to -1.99], 8 KKW: -4.06 [-6.45 to -1.67], 12 KKW: -6.22 [-8.68 to -3.77]; $P=.04$), with a significant dose-response trend observed ($P=.02$). Exercise training participants had lower odds of having significant sleep disturbance at post-intervention compared to control (4 KKW OR: 0.37 [0.19 to 0.73], 8 KKW: 0.36 [0.17 to 0.77], 12 KKW: 0.34 [0.16 to 0.72]). The magnitude of weight loss

1
2
3 did not differ between treatment conditions. Improvements in sleep quality were not related to
4
5 changes in body weight, resting parasympathetic control, or cardiorespiratory fitness.
6
7

8 **Conclusion:** Exercise training induced significant improvement in subjective sleep quality in
9
10 postmenopausal women, with even a low dose of exercise resulting in greatly reduced odds of
11
12 having significant sleep disturbance.
13

14
15 **Trial registration:** clinicaltrials.gov identifier: NCT00011193.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article Focus:

- Sleep disturbance is prevalent in postmenopausal women, with 35-60% reporting significant sleep problems.
- Effective, safe and easily available treatment options for disturbed sleep in postmenopausal women are lacking.
- There has been equivocal evidence as to whether exercise improves sleep in postmenopausal women, though possible dose-response effects have been noted.

Key Messages:

- Exercise resulted in significant improvement in subjective sleep quality in postmenopausal women, with reduced odds of having sleep disturbance at post-intervention with even 50% of the recommended dose of exercise for adults.
- The effects of exercise on sleep quality were independent of changes in body weight, resting parasympathetic control, or cardiorespiratory fitness.

Strengths and Limitations:

- The study constitutes the largest randomised controlled trial on exercise and sleep quality, using a structured dose of exercise and a validated measure of sleep quality.
- Only self-reported sleep was assessed; objective measurement of sleep, with either actigraphy or polysomnography, was not conducted.
- Despite the high prevalence of sleep disturbance in the sample, participants were not selected on the basis of sleep complaints.

INTRODUCTION

Disturbed sleep is a common complaint among women, with increasing prevalence beginning at the menopausal transition. Postmenopausal women are more likely to report sleep problems than premenopausal or perimenopausal women,[1] with 35-60% of postmenopausal women reporting significant sleep problems.[2] The first-line treatment options for sleep complaints, hypnotic medication and cognitive behavioral therapy, have associated concerns about the safety of long-term use or treatment availability, respectively.[3,4] Furthermore, results are conflicting on the effect of hormone replacement therapy (HRT) on sleep quality,[5,6] despite the effectiveness of HRT at reducing other menopausal symptoms.

A nonpharmacological treatment that has been traditionally thought to improve sleep is exercise. In epidemiologic research, exercise has frequently been associated with better sleep.[7] However, experimental research has provided less compelling evidence,[8] particularly when regarding postmenopausal women. Of the four randomised trials that have investigated the effect of exercise on sleep quality in this population,[9-12] only one reported a significant improvement in subjective sleep quality following an exercise intervention.[12] However, despite the generally negative findings from these studies involving postmenopausal women, possible dose-response effects of exercise on sleep quality were noted. In one of these studies, women who performed at least 225 minutes of morning exercise per week had less trouble falling asleep compared to those who exercised less than 180 minutes per week in the morning.[9] Likewise, another study reported a positive association between walking frequency and improvements in sleep.[11]

To our knowledge, no research has directly investigated the effects of different doses of exercise on sleep quality. The Dose-Response to Exercise in postmenopausal Women (DREW) trial was conducted to investigate the health effects of 50%, 100%, and 150% of the NIH

1
2
3 Consensus Development Panel physical activity recommendations in a group of sedentary
4
5 postmenopausal women.[13] Results on the primary outcomes of the study, cardiorespiratory
6
7 fitness and blood pressure, have already been reported.[14] Subjective sleep quality was also
8
9 assessed in this trial as an exploratory outcome, and the data provided herein provides the first
10
11 systematic examination of whether a dose-response relationship exists between exercise and
12
13 subjective sleep quality. It was hypothesised that, in comparison to a non-exercise control group,
14
15 subjective sleep quality would improve with increasing dosage of exercise.
16
17
18

19 20 METHODS

21
22 A complete description of the recruitment and screening procedures has been published
23
24 elsewhere.[13] Briefly, the study was a randomised, controlled, multi-arm parallel group trial in
25
26 which the primary outcomes were examining whether there were dose-response effects on
27
28 cardiorespiratory fitness and blood pressure with incrementally increasing doses of energy
29
30 expenditure.[13,14] The study was approved annually by the Cooper Institute Institutional
31
32 Review Board, and written informed consent was obtained by all participants prior to study
33
34 involvement.
35
36
37

38 39 Participants

40
41 Participants were recruited from the Dallas, Texas, metropolitan area from April 2001 to
42
43 June 2005. Of 4545 women screened for eligibility, those who were aged 45-75 years,
44
45 postmenopausal, sedentary (≤ 20 min of exercise on ≤ 2 days/week and < 8000 steps/day,
46
47 averaged over one week), overweight or obese (body mass index [BMI] of 25-43 kg/m²), and
48
49 had normal to mildly elevated resting blood pressure (systolic blood pressure [SBP] of 120-159
50
51 mm Hg and diastolic blood pressure [DBP] ≤ 99 mm Hg) were eligible to participate (Figure 1).
52
53 Exclusion criteria included significant cardiovascular disease, recent hospitalisation for mental
54
55
56
57
58
59
60

1
2
3 illness or significant symptoms of depression (score ≥ 10 on the Center for Epidemiologic
4
5 Studies Depression scale), or any other health condition that would contraindicate participation
6
7
8 in an exercise program. Overall, 464 women were randomised to treatment, with baseline sleep
9
10 data available for 437 participants.

11 12 **Randomisation and Retention**

13
14
15 Prior to randomisation, participants completed a two-week run-in period, in which
16
17 participants received lifestyle modification instruction over the course of six laboratory visits.
18
19 The primary purpose of this run-in period was to maximise retention and adherence to the
20
21 subsequent intervention. Participants were compensated for completing baseline and post-
22
23 intervention assessments, with additional compensation based on intervention adherence.[13]
24
25
26

27 Allocation of participants to treatment conditions was accomplished using a computer-
28
29 generated randomisation sequence, determined from randomly permuted blocks of equal length
30
31 with fixed numbers of treatment allotments to balance treatment enrollments over time.

32
33 Allocation concealment was achieved by placing treatment assignment letters into sequentially
34
35 numbered opaque envelopes sealed by the study statistician. At the time of randomisation,
36
37 envelopes were opened by a staff member not affiliated with the randomisation process.[13]
38
39
40

41 Participants were randomised to one of four treatment conditions: a non-exercise control
42
43 group, or one of three exercise groups expending 4, 8, or 12 kilocalories per kilogram of body
44
45 weight per week (KKW). Energy expenditure levels for the exercise groups were designed to
46
47 correspond with 50%, 100%, and 150% of the NIH Consensus Development Panel physical
48
49 activity recommendations, respectively.[15]
50
51
52

53 **Interventions**

54
55
56
57
58
59
60

1
2
3 Women assigned to the exercise groups participated in 3-4 training sessions/week for 6
4 months, alternating between semirecumbent cycle ergometer and treadmill exercise. Training
5 sessions were conducted in a supervised laboratory setting, and exercise dosage was closely
6 monitored for each session. Training intensity was moderate, set at the heart rate associated with
7 50% of each woman's VO_{2peak} and continuously monitored by heart rate telemetry. To determine
8 the number of calories that needed to be expended each week, participants were weighed weekly
9 and their weight was multiplied by the exercise dosage.
10
11
12
13
14
15
16
17
18

19
20 Exercise dose was gradually increased to minimise injury risk. All exercise training
21 groups expended 4 KKW during the first intervention week, with the 4-KKW group continuing
22 at that dose for 6 months. The 8- and 12-KKW groups increased their energy expenditure by 1
23 KKW until they reached their appointed exercise doses.
24
25
26
27
28

29 **Blinding**

30
31 Although participants could not be blinded to their treatment, staff were separated into
32 intervention and assessment teams to ensure blinding of all assessment staff to participant
33 randomisation assignment. Participants were consistently reminded to refrain from discussing
34 their randomisation assignments with outcome assessment staff.
35
36
37
38
39
40

41 **Sleep Measure**

42
43 Subjective sleep quality was assessed with six items from the Medical Outcomes Study
44 (MOS) Sleep Scale.[16] At baseline and post-intervention, participants were asked to respond
45 based on their sleep during the previous four weeks. One question, which addressed the length of
46 time to fall asleep, was framed with five response options ranging from 0-15 minutes to > 60
47 minutes. For the remaining five questions (i.e., restless sleep, daytime drowsiness, difficulty
48 falling asleep, awakening from sleep and experiencing difficulty returning to sleep, staying
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 awake during the day), participants were asked to respond on a 5-point scale, ranging from “none
4 of the time” to “all of the time”. Item responses were assigned scores using conventional scoring
5 rules, with higher scores indicating a greater severity of sleep disturbance. A modified Sleep
6 Problems Index (SPI), utilising all six sleep items, provided a measure of overall sleep
7 quality.[17] SPI scores greater than 25 were considered to indicate significant sleep disturbance,
8 as prior work utilising a 9-item SPI reported that a cutpoint of > 25 identified individuals who
9 considered themselves to have a sleep problem with a sensitivity of 86.2% and specificity of
10 66.3%.[17]

11
12 Scores on the MOS Sleep Scale have been shown to correlate with other MOS health
13 items,[16] differentiate between those with and without chronic health conditions,[17] and
14 improve with treatment of chronic health conditions.[18] Normative values for the general
15 population have also been developed.[17]

31 **Other Measures**

32
33
34 Baseline demographic and health characteristics were assessed by completion of a
35 comprehensive medical history questionnaire. Height and weight were measured with a
36 calibrated stadiometer and electronic scale, respectively. Diet was assessed before and following
37 the intervention using a semi-quantitative food frequency questionnaire, whereas unsupervised
38 physical activity was monitored throughout the study with a pedometer (Accusplit Eagle, Japan).

39
40
41 Cardiorespiratory fitness (VO_{2peak}) was assessed from maximal exercise testing using a
42 cycle ergometer (Excalibur Sport, Lode Medical Technology, Groningen, Netherlands), as
43 previously described.[14] Testing was performed twice at baseline and twice at post-
44 intervention, with values from each timepoint averaged. Heart rate variability (HRV) was
45 measured from the final 5 min of a 25-min resting assessment, as previously described.[19] The

1
2
3 square root of the mean of the sum of the squares of differences between adjacent R-R intervals
4
5 (rMSSD), a marker of parasympathetic activity,[20] was retained for analysis.
6
7

8 **Statistical Power**

9
10 Sample size was originally based on having adequate power to detect changes in the
11 primary outcomes of the overall study, VO_{2peak} and blood pressure.[14] Additional participants
12 were allocated to the 4 KKW condition to increase statistical power for detecting smaller
13 anticipated fitness gains in this group. Because sleep was not a primary outcome in the design of
14 the original study, there was no opportunity before data collection to investigate sample size or
15 power for this outcome variable. Nevertheless, given the current enrollment, the study had 84%
16 power (assuming two-tailed $\alpha = 0.05$) to detect an effect size of 0.20 for MOS SPI score
17 reduction.
18
19
20
21
22
23
24
25
26
27
28

29 **Statistical Analysis**

30
31 Baseline sleep quality was compared against normative data[17] using a one-sample *t*-
32 test. Continuous MOS SPI values were examined across quartiles of BMI, parasympathetic tone
33 (rMSSD), and cardiorespiratory fitness (VO_{2peak}) with analysis of covariance (ANCOVA),
34 controlling for age, BMI, sleep medication use, and HRT use. The likelihood of having
35 significant sleep disturbance at baseline (i.e., MOS SPI > 25) was evaluated with logistic
36 regression across the same quartiles using the same covariates.
37
38
39
40
41
42
43
44
45

46 Two primary outcomes were evaluated for the current study: (1) change in continuous
47 MOS SPI score across treatment groups; (2) odds of having significant sleep disturbance at post-
48 intervention across treatment groups. Change in continuous MOS SPI scores across groups was
49 tested by ANCOVA, with adjustment for age, BMI, sleep medication use, HRT use, and baseline
50 MOS SPI values. All assumptions underlying the ANCOVA models were checked and verified
51
52
53
54
55
56
57
58
59
60

1
2
3 to be met. Individual treatment groups were compared to the control group with Tukey-Kramer
4 adjustment for multiple comparisons. An α level of .05 was used because it was our *a priori*
5 intention to compare only the separate treatment groups with the control group. Dose-response
6 trends were analysed using least-squares regression of MOS SPI change across groups. Logistic
7 regression examined the odds of having significant sleep disturbance at post-intervention,
8 following adjustment for age, BMI, sleep medication and HRT use, and baseline sleep
9 disturbance ($SPI > 25$, $SPI \leq 25$). Unadjusted analyses provided similar results to those with
10 covariate control, so only those results with full covariate adjustment were reported.
11
12

13
14
15 Finally, to examine whether improved sleep quality was significantly influenced by body
16 weight, parasympathetic tone, or cardiorespiratory fitness, changes in weight, rMSSD, and
17 VO_{2peak} were added to the ANCOVA and logistic regression analyses. Additionally, among
18 completed participants, changes in MOS SPI score were evaluated across quartiles of change in
19 body weight, rMSSD, and VO_{2peak} following adjustment for age, treatment, BMI, sleep
20 medication use, HRT use, and baseline MOS SPI score.
21
22

23
24
25 Analyses were limited to participants with baseline MOS Sleep data. Primary analyses
26 were conducted using the intent-to-treat principle; if post-intervention data were missing,
27 baseline values were carried forward for analysis. When analyses were restricted to only those
28 participants with baseline and post-intervention MOS Sleep data ($n = 359$), results were not
29 substantively changed; similarly, when missing post-intervention data were imputed with mean
30 values, results were unchanged. Therefore, only intent-to-treat analyses were presented. All
31 analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). All tests were two-
32 tailed, with statistical significance set at $P \leq .05$.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 55 56 57 58 59 60

RESULTS

Participant Characteristics

A summary of participant characteristics is provided in Table 1. Mean age and BMI of the 437 participants were 57.3 ± 6.5 yr and 31.8 ± 3.9 kg/m², respectively.

Baseline MOS SPI values and prevalence of sleep disturbance are provided in Table 1. Of the 437 participants, 46% of the sample ($n = 200$) were considered to have significant sleep disturbance at baseline, as defined as MOS SPI > 25. Baseline sleep quality of the participants was significantly worse than normative values[17] (normative value: 25.79; $t_{436} = 2.42$, $P = .02$), a magnitude of 0.12 SD.[21]

Baseline continuous MOS SPI values and odds of sleep disturbance across quartiles of BMI, rMSSD, and VO_{2peak} are shown in Table 2. Sleep quality significantly differed among quartiles of rMSSD ($F_{3,343} = 2.55$, $P = .05$), with the lowest quartile of rMSSD having significantly worse baseline sleep quality than the other quartiles of rMSSD. Similarly, each quartile of rMSSD was associated with lower odds of having significant sleep disturbance at baseline compared to the lowest quartile of rMSSD. No differences in MOS SPI values or odds of having significant sleep disturbance were observed across quartiles of BMI or VO_{2peak}.

Exercise Training Adherence, Diet and Unsupervised Activity

Treatment adherence was calculated as the percentage of exercise energy expenditure achieved compared to the amount of exercise energy expenditure that was prescribed. Adherence was similar between exercise groups (4 KKW: $95.1 \pm 16.1\%$, 8 KKW: $88.5 \pm 26.1\%$, 12 KKW: $92.5 \pm 20.9\%$), as previously reported.[14]

Changes in diet and unsupervised activity have been previously reported.[14,22] Pre- to post-intervention changes in energy intake did not differ between treatment conditions.

Pedometer-assessed unsupervised activity ranged from 4766 to 5067 steps/day at baseline and

1
2
3 did not differ between groups. Compared to baseline, daily steps increased for each group at
4 month 1 (each $P < .05$), with greater steps in the control group than the three exercise groups
5 (each $P < .05$). However, no differences in daily steps between the control and exercise groups
6 were observed by months 5 and 6. Among the exercise groups, daily steps did not change from
7 months 1 through 6. Therefore, the results reported here are unlikely to be due to changes in diet
8 or spontaneous activity outside the exercise training laboratory.
9

10 11 12 13 14 15 16 17 18 **Changes in Sleep Quality with Exercise Training**

19
20 Changes in sleep quality with exercise training are depicted in Figure 2. A significant
21 effect of the intervention was noted in the full model ($F_{8,428} = 17.35, P < .001$), with treatment
22 group being an independent predictor of change in continuous MOS SPI score ($F_{3,428} = 2.79, P =$
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2

1
2
3 1.08 [3.70], 4 KKW: -1.23 [3.43], 8 KKW: -1.60 [3.23], 12 KKW: -1.25 [2.83] kg; $F_{3,433} = 0.43$,
4
5 $P = .73$). Cardiorespiratory fitness improved with exercise training in a dose-dependent manner

6
7 (control: -0.20 [1.88], 4 KKW: 0.59 [1.83], 8 KKW: 1.13 [1.54], 12 KKW: 1.42 [1.79]

8
9 mL/kg/min; $F_{3,433} = 15.32$, $P < .001$). Among those with usable HRV and sleep data ($n = 351$),

10
11 rMSSD improved in a dose-dependent fashion with exercise training (control: 0.20 [8.45], 4

12
13 KKW: 2.72 [9.20], 8 KKW: 3.72 [11.47], 12 KKW: 5.29 [9.51] ms; $F_{3,347} = 3.82$, $P = .01$).

14
15 When added to the model analysing differences in continuous MOS SPI change among treatment

16
17 groups, none of these covariates were significant ($P \leq .14$), and inclusion of these variables did

18
19 not alter the previously noted treatment group differences or linear dose-response effects. When

20
21 individually added to logistic regression analyses, none of these covariates significantly affected

22
23 the odds of having significant sleep disturbance at post-intervention (Table 3). In addition, when

24
25 change in MOS SPI was evaluated across quartiles of change in body weight, rMSSD, or

26
27 VO_{2peak} , no significant-between group differences were noted (data not shown). Finally, change

28
29 in MOS SPI did not correlate with change in body weight, rMSSD or VO_{2peak} ($r < .03$, $P > .58$).

30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

DISCUSSION

The key finding from exploratory analyses of the DREW randomised controlled trial was

that exercise training significantly improved subjective sleep quality in overweight/obese

postmenopausal women. Specifically, we observed a dose-response trend for the continuous

MOS SPI values and, perhaps most notably, significantly reduced odds of having sleep

disturbance at post-intervention with even 50% of the recommended dose of exercise for adults.

Interestingly, the improvements in sleep quality were not related to changes in body weight,

parasympathetic tone, or cardiorespiratory fitness.

Previous research

1
2
3 Previous research with postmenopausal women had yielded conflicting findings
4 regarding whether exercise improved sleep.[9-12] While suggested by prior studies in this
5 population,[9,11] the present study is the first to document a dose-response relationship between
6 exercise and improved subjective sleep quality. Although sleep was an exploratory outcome of
7 the DREW study, it is the largest clinical trial to date that has examined the relationship between
8 aerobic exercise dose and sleep quality. Our current findings mirror the overall body of research
9 indicating that exercise improves sleep, most prominently in those with existing sleep
10 disturbances.[8]
11
12
13
14
15
16
17
18
19
20
21

22 **Clinical implications**

23
24 When considering the improvements in continuous MOS SPI scores following exercise
25 training, the clinical significance is uncertain. The observation that only those who exercised at a
26 12-KKW dose experienced a significant improvement in sleep quality compared to control may
27 be viewed as discouraging, as this dose equated to approximately 190 min/wk of moderate-
28 intensity aerobic exercise[14] and many individuals may not be willing to perform that much
29 exercise to improve sleep. However, the significant dose-response effect suggests that any dose
30 of exercise should benefit sleep, albeit with larger effects noted with higher levels of energy
31 expenditure.
32
33
34
35
36
37
38
39
40
41
42

43 In contrast, the greatly reduced odds of having significant sleep disturbance following
44 exercise training suggests that exercise may hold the most promise as a treatment option for
45 postmenopausal women with significant sleep disturbance. In particular, even an exercise dose
46 consisting of 50% of the NIH Consensus Panel physical activity recommendations significantly
47 reduced the odds of having a post-intervention MOS SPI > 25. This is noteworthy, since sleep
48 complaints are prevalent in postmenopausal women[1] and current treatment options, such as
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 HRT and hypnotic medication, have often been found to be only mildly efficacious at improving
4 sleep quality compared to placebo in postmenopausal women.[6,23]
5
6

7
8 The mechanisms by which exercise may improve subjective sleep quality in
9
10 postmenopausal women are unknown. Although the present study was not specifically designed
11 to address mechanisms of effect, secondary analyses focused on changes in three variables which
12 have been shown to be related to sleep: body weight, parasympathetic activity, and
13 cardiorespiratory fitness. There is a clear association between obesity and disturbed sleep,[24]
14 and weight loss has been found to reduce sleep complaints.[25] Likewise, poor sleepers have
15 been found to have impaired sleep HRV,[26] and exercise training has been well-documented to
16 improve autonomic function.[27] Finally, physical fitness has been previously associated with
17 sleep quality,[28] and greater improvements in fitness have been associated with better sleep
18 outcomes in some experimental studies.[9,12]
19
20
21
22
23
24
25
26
27
28
29
30

31
32 Nonetheless, in the present study, changes in body weight, parasympathetic tone, or
33 cardiorespiratory fitness were not significantly related to changes in sleep, whether assessed by
34 covariate control, change in sleep quality across quartiles of change in these variables, or
35 correlations between change in these variables and change in sleep quality. Although significant
36 improvements were noted for rMSSD and VO_{2peak} following exercise training in this
37 sample,[14,19] the variability associated with the sleep measure used in the current study may
38 have masked any possible associations. The present study suggests that exercise training can
39 result in improved sleep quality independent of weight loss, increased fitness, or improved
40 autonomic balance.
41
42
43
44
45
46
47
48
49
50
51

52 **Strengths and weaknesses**

53
54
55
56
57
58
59
60

1
2
3
4 Strengths of the study include a randomised controlled design, closely supervised
5
6 intervention, use of a validated measure of sleep quality, and the largest experimental sample
7
8 size to investigate the effects of exercise on sleep. The study population was another strength, as
9
10 the prevalence of disturbed sleep was high. Finally, assessment of variables that are related to
11
12 sleep quality and may contribute to improved sleep following exercise training was another
13
14 strength of the study.
15

16
17 A limitation of the study is that sleep quality was not a primary outcome of the original
18
19 DREW trial. Therefore, results should be interpreted cautiously. Another study limitation is that
20
21 sleep was not objectively assessed (i.e., via wrist actigraphy or polysomnography). Because of
22
23 the subjective nature of the outcome and impossibility of blinding participants to their treatment,
24
25 improvements in self-reported sleep quality may have been subject to expectancy effects, as
26
27 exercise is commonly believed to improve sleep quality.[7] However, the finding of a significant
28
29 linear trend between exercise dose and improvement in sleep quality would not necessarily be
30
31 expected. Moreover, that sleep was not a primary outcome of interest and part of a wide range of
32
33 study assessments further reduces the chance of expectancy or demand biases. Additionally,
34
35 there is growing recognition of the merit of assessing subjective sleep quality.[29] For instance,
36
37 in contrast with subjective sleep quality, objective sleep has not been found to be altered across
38
39 the menopausal transition.[30] Furthermore, impaired subjective sleep quality is what prompts
40
41 search for treatment, and recent evidence suggests that traditional objective sleep measures might
42
43 be inadequate for detecting subtle indicators of disturbed sleep.[31] It is also noteworthy that
44
45 subjective sleep quality has been associated with quality of life and physical and mental health in
46
47 postmenopausal women.[32]
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 A lack of assessment of obstructive sleep apnoea (OSA) was another limitation. Although
4
5 OSA is considered to be a male-dominated sleep disorder, postmenopausal OSA prevalence is
6
7 similar between males and females.[33] Moreover, excess weight is the primary cause of OSA
8
9 for most adults,[34] which would place this overweight/obese sample at even higher risk for
10
11 OSA. Evidence suggests that exercise, in the absence of more established treatments or
12
13 significant weight loss, is moderately efficacious at reducing OSA severity and improving
14
15 sleep.[35] However, dose-response effects of exercise on OSA severity are unknown.
16
17
18

19
20 Finally, because aerobic activity was the only mode of exercise studied in the DREW
21
22 trial, the possible effects of resistance exercise on sleep quality could not be examined in this
23
24 sample. Resistance training has been shown to improve sleep quality,[36] though there has been
25
26 minimal work comparing different doses of resistance exercise on sleep quality.[37]
27
28

29 **Conclusions**

30
31 In summary, in a sample of overweight/obese postmenopausal women, exercise training
32
33 significantly reduced the odds of having significant sleep disturbance. These improvements in
34
35 sleep were independent of the effects of exercise training on body weight, parasympathetic tone,
36
37 or cardiorespiratory fitness. Additional research with more comprehensive measurement of sleep
38
39 is warranted, but exercise training appears to significantly improve sleep quality in
40
41 postmenopausal women.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

We thank the DREW participants and the Cooper Institute staff for their efforts on this study.

Contributors: TSC and SNB designed and organised the study. TSC, CPE, and SNB collected the data. CEK and XS performed the statistical analyses. CEK wrote the first draft of the manuscript. XS, MHH, SDY, CPE, SNB, and TSC provided critical input at all stages and critically reviewed and contributed to the final draft. CEK and TSC are guarantors.

Funding: This work was supported by grants HL66262 and T32 HL082610-05 from the National Institutes of Health, and American Heart Association Texas Affiliate award 02651404. Life Fitness (Schiller Park, Illinois) provided exercise equipment for this study.

Competing interest statement: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work (aside from the funding sources listed); no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Institutional Review Boards of the Cooper Institute (Dallas, TX) and the Pennington Biomedical Research Center (Baton Rouge, LA).

Role of the study sponsors: The sponsors had no role in the study design, protocol development, or in conducting the trial, data collection, data analysis, or preparation of the manuscript.

Data sharing: The data set will be available from the corresponding author as part of an academic collaboration.

Trial registration: Clinicaltrials.gov identification number NCT00011193.

REFERENCES

1. Kravitz HM, Ganz PA, Bromberger J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. *Menopause* 2003;10:19-28.
2. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. *Ann Intern Med* 2005;142:1003-13.
3. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. *J Gen Intern Med* 2007;22:1335-50.
4. Nowakowski S, Meliska CJ, Martinez LF, et al. Sleep and menopause. *Curr Neurol Neurosci Rep* 2009;9:165-72.
5. Sarti CD, Chiantera A, Graziottin A, et al. Hormone therapy and sleep quality in women around menopause. *Menopause* 2005;12:545-51.
6. Kalleinen N, Polo O, Himanen SL, et al. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. *Climacteric* 2008;11:233-43.
7. Youngstedt SD, Kline CE. Epidemiology of exercise and sleep. *Sleep Biol Rhythms* 2006;4:215-21.
8. Youngstedt SD. Effects of exercise on sleep. *Clin Sports Med* 2005;24:355-65.
9. Tworoger SS, Yasui Y, Vitiello MV, et al. Effects of a yearlong moderate-intensity exercise and a stretching intervention on sleep quality in postmenopausal women. *Sleep* 2003;26:830-6.
10. Elavsky S, McAuley E. Lack of perceived sleep improvement after 4-month structured exercise programs. *Menopause* 2007;14:535-40.

- 1
2
3 11. Wilbur J, Miller AM, McDevitt J, et al. Menopausal status, moderate-intensity walking, and
4 symptoms in midlife women. *Res Theory Nurs Pract* 2005;19:163-80.
5
6
- 7
8 12. King AC, Oman RF, Brassington GS, et al. Moderate-intensity exercise and self-rated
9 quality of sleep in older adults. A randomized controlled trial. *JAMA* 1997;277:32-7.
10
11
- 12 13. Morss GM, Jordan AN, Skinner JS, et al. Dose Response to Exercise in Women aged 45-75
13 yr (DREW): design and rationale. *Med Sci Sports Exerc* 2004;36:336-44.
14
15
- 16 14. Church TS, Earnest CP, Skinner JS, et al. Effects of different doses of physical activity on
17 cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women
18 with elevated blood pressure: a randomized controlled trial. *JAMA* 2007;297:2081-91.
19
20
- 21 15. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health.
22 Physical activity and cardiovascular health. *JAMA* 1996;276:241-6.
23
24
- 25 16. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, Jr., eds. *Measuring*
26 *Functioning and Well-being: The Medical Outcomes Study Approach*. Durham, NC: Duke
27 University Press 1992:235-59.
28
29
- 30 17. Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the Medical Outcomes
31 Study Sleep measure. *Sleep Med* 2005;6:41-4.
32
33
- 34 18. Allen RP, Kosinski M, Hill-Zabala CE, et al. Psychometric evaluation and tests of validity
35 of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). *Sleep Med* 2009;10:531-
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Earnest CP, Lavie CJ, Blair SN, et al. Heart rate variability characteristics in sedentary
postmenopausal women following six months of exercise training: the DREW study. *PLoS*
One 2008;3:e2288.

- 1
2
3 20. Task Force of the European Society of Cardiology and the North American Society of
4 Pacing and Electrophysiology. Heart rate variability: standards of measurement,
5 physiological interpretation, and clinical use. *Eur Heart J* 1996;17:354-81.
6
7
- 8
9 21. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Philadelphia, PA:
10 Lawrence Erlbaum Associates, Inc. 1988.
11
12
- 13 22. Church TS, Martin CK, Thompson AM, et al. Changes in weight, waist circumference and
14 compensatory responses with different doses of exercise among sedentary, overweight
15 postmenopausal women. *PLoS One* 2009;4:e4515.
16
17
- 18 23. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during
19 perimenopause and early postmenopause: a randomized controlled trial. *Obstet Gynecol*
20 2006;108:1402-10.
21
22
- 23 24. Fogelholm M, Kronholm E, Kukkonen-Harjula K, et al. Sleep-related disturbances and
24 physical inactivity are independently associated with obesity in adults. *Int J Obes (Lond)*
25 2007;31:1713-21.
26
27
- 28 25. Dixon JB, Schachter LM, O'Brien PE. Sleep disturbance and obesity: changes following
29 surgically induced weight loss. *Arch Intern Med* 2001;161:102-6.
30
31
- 32 26. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers.
33 *Psychosom Med*. 1998;60:610-5.
34
35
- 36 27. Routledge FS, Campbell TS, Fetridge-Durdle JA, et al. Improvements in heart rate
37 variability with exercise therapy. *Can J Cardiol* 2010;26:303-12.
38
39
- 40 28. Lee AJ, Lin WH. Association between sleep quality and physical fitness in female young
41 adults. *J Sports Med Phys Fitness* 2007;47:462-7.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
29. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
30. Young T, Rabago D, Zgierska A, et al. Objective and subjective sleep quality in premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort Study. *Sleep* 2003;26:667-72.
31. Perlis ML, Smith MT, Andrews PJ, et al. Beta/Gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. *Sleep* 2001;24:110-7.
32. Baker FC, Wolfson AR, Lee KA. Association of sociodemographic, lifestyle, and health factors with sleep quality and daytime sleepiness in women: findings from the 2007 National Sleep Foundation "Sleep in America Poll". *J Womens Health* 2009;18:841-9.
33. Young T, Finn L, Austin D, et al. Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. *Am J Respir Crit Care Med* 2003;167:1181-5.
34. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl Physiol* 2005;99:1592-9.
35. Kline CE, Crowley EP, Ewing GB, et al. The effect of exercise training on obstructive sleep apnea and sleep quality: a randomized controlled trial. *Sleep* 2011;34:1631-40.
36. Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of the effect of exercise on sleep. *Sleep* 1997;20:95-101.
37. Singh NA, Stavrinou TM, Scarbek Y, et al. A randomized controlled trial of high versus low intensity weight training versus general practitioner care for clinical depression in older adults. *J Gerontol A Biol Sci Med Sci* 2005;60:768-76.

FIGURE LEGENDS

Figure 1. *Participant screening and study flow.* Of 4545 screened for participation, 464 postmenopausal women were randomised to one of four treatments. Baseline MOS Sleep data were available for 437 participants; those who discontinued the study or without follow-up MOS Sleep data had baseline data carried forward for analysis. BMI: body mass index; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

Figure 2. *Change in MOS Sleep Problems Index scores among treatment groups.* Data presented as least-squares means \pm 95% confidence intervals. Analyses adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and baseline MOS SPI score. * Indicates difference from control ($P = .02$). KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

TABLES

Table 1. Baseline Participant Characteristics.

	All (N=437)	Control (n=92)	Exercise Groups		
			4 KKW (n=151)	8 KKW (n=99)	12 KKW (n=95)
Age, y	57.32 (6.46)	57.14 (5.91)	57.78 (6.53)	57.58 (6.63)	56.47 (6.72)
Education, y	14.03 (2.11)	14.01 (2.12)	13.80 (2.02)	14.37 (2.06)	14.00 (2.28)
Married, No. (%)	398 (91)	86 (93)	141 (94)	87 (88)	84 (88)
Ethnicity/race, No. (%)					
White	278 (64)	58 (63)	92 (61)	60 (61)	68 (72)
African-American	128 (29)	23 (25)	49 (32)	32 (32)	24 (25)
Hispanic/Other	31 (7)	11 (12)	10 (7)	7 (7)	3 (3)
Employed, No. (%)	304 (70)	62 (67)	105 (70)	67 (68)	70 (74)
Cigarette Smoking, No. (%)	25 (6)	5 (5)	8 (5)	4 (4)	8 (8)
Medication Use, No. (%)					
Antihypertensive	126 (29)	22 (24)	41 (27)	32 (32)	31 (33)
Hyperlipidemia	73 (17)	14 (15)	31 (21)	17 (17)	11 (12)
Thyroid	65 (15)	12 (13)	19 (13)	16 (16)	18 (19)
Antidepressant	78 (18)	16 (17)	28 (19)	18 (18)	16 (17)
HRT	202 (46)	48 (52)	67 (44)	43 (43)	44 (46)
Antianxiety	20 (5)	7 (8)	7 (5)	4 (4)	2 (2)
Sedatives/sleep aids	12 (3)	4 (4)	5 (3)	3 (3)	0 (0)
Energy Intake, kcal/d	2277.2 (952.6)	2277.4 (947.9)	2213.1 (941.6)	2290.7 (930.7)	2364.7 (1003.5)
Anthropometrics					
Weight, kg	84.46 (11.82)	85.77 (12.43)	83.56 (11.42)	84.74 (12.43)	84.33 (11.24)
Body mass index, kg/m ²	31.77 (3.85)	32.29 (3.94)	31.54 (3.80)	31.98 (4.08)	31.44 (3.58)
Cardiorespiratory Fitness					
Relative VO _{2peak} , mL/kg/min	15.37 (2.92)	15.56 (3.00)	15.44 (3.00)	14.70 (2.49)	15.77 (3.05)
Absolute VO _{2peak} , L/min	1.29 (0.26)	1.33 (0.28)	1.28 (0.24)	1.24 (0.24)	1.32 (0.26)
Heart Rate Variability [*]					
rMSSD, ms	22.83 (11.56)	23.35 (11.01)	23.58 (12.24)	23.25 (11.29)	20.68 (11.19)
Subjective Sleep Quality					
MOS Sleep Problems Index	27.92 (18.40)	28.37 (19.71)	27.03 (17.92)	27.35 (18.10)	29.47 (18.32)
Sleep disturbance, No. (%)	200 (46)	38 (41)	65 (43)	49 (49)	48 (51)

Data presented as mean (standard deviation) unless otherwise indicated. * Samples for rMSSD

data were 351, 79, 123, 73, and 76 participants for All, Control, 4 KKW, 8 KKW, and 12 KKW groups, respectively. Abbreviations: HRT: hormone replacement therapy; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study; rMSSD: square root of the mean of the sum of the squares of differences between adjacent R-R intervals; VO_{2peak}: peak rate of oxygen consumption.

Table 2. Associations Between Baseline Sleep Quality and BMI, Parasympathetic Tone, and Cardiorespiratory Fitness.

Variable	MOS SPI score (95% CI)	OR of MOS SPI > 25 (95% CI)
BMI (kg/m²)		
Q1: ≥ 34.7	27.95 (24.54, 31.36)	1.00 (referent)
Q2: 31.7 - < 34.7	24.37 (20.92, 27.82)	0.60 (0.35, 1.03)
Q3: 28.6 - < 31.7	30.48 (27.03, 33.94)	1.14 (0.67, 1.96)
Q4: < 28.6	28.85 (25.46, 32.24)	0.98 (0.58, 1.68)
Linear <i>P</i>	.26	.53
rMSSD (ms)		
Q1: < 15.0	31.77 (27.95, 35.59)	1.00 (referent)
Q2: 15.0 - < 20.9	24.77 (21.04, 28.51)*	0.53 (0.29, 0.97)
Q3: 20.9 - < 29.0	25.22 (21.36, 29.09)*	0.43 (0.23, 0.81)
Q4: ≥ 29.0	26.50 (22.64, 30.35)*	0.46 (0.25, 0.86)
Linear <i>P</i>	.08	.01
VO_{2peak} (mL/kg/min)		
Q1: < 13.4	29.55 (25.86, 33.25)	1.00 (referent)
Q2: 13.4 - < 15.2	28.80 (25.35, 32.25)	1.22 (0.70, 2.13)
Q3: 15.2 - < 17.0	28.60 (25.05, 32.15)	1.04 (0.58, 1.87)
Q4: ≥ 17.0	24.91 (21.41, 28.42)	0.63 (0.34, 1.14)
Linear <i>P</i>	.10	.09

Continuous baseline MOS SPI scores (left panels) and odds ratios of having significant sleep disturbance at baseline (MOS SPI > 25) (right panels) across quartiles of baseline BMI, rMSSD, and VO_{2peak}. All analyses adjusted for age, BMI, sleep medication use, and HRT use, except when the covariate quartile was the independent variable. * indicates significant difference ($P \leq .05$) in MOS SPI score compared to quartile 1 (referent group). Abbreviations: BMI: body mass index; CI: confidence interval; MOS: Medical Outcomes Study; Q: quartile; rMSSD: square root of the mean of the sum of the squares of differences between adjacent R-R intervals; SPI: Sleep Problems Index; VO_{2peak}: peak rate of oxygen consumption.

Table 3. Prevalence and Odds of Significant Sleep Disturbance (i.e., MOS SPI > 25) at Post-Intervention.

	Prevalence	Model 1	Model 2	Model 3	Model 4
	<i>n</i> (%)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
Control	41 (45%)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
4 KKW	46 (31%)	0.37 (0.19, 0.73)	0.37 (0.19, 0.73)	0.34 (0.19, 0.73)	0.37 (0.19, 0.73)
8 KKW	33 (33%)	0.36 (0.17, 0.77)	0.36 (0.17, 0.77)	0.32 (0.17, 0.77)	0.36 (0.17, 0.77)
12 KKW	31 (33%)	0.34 (0.16, 0.72)	0.34 (0.16, 0.72)	0.28 (0.16, 0.72)	0.34 (0.16, 0.72)
Linear trend <i>P</i>		.01	.01	.006	.02
Weight change		---	1.00 (0.93, 1.08)	---	---
VO _{2peak} change		---	---	1.10 (0.95, 1.26)	---
rMSSD change		---	---	---	1.01 (0.98, 1.04)

Model 1 adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and

baseline sleep quality (SPI ≤ 25, SPI > 25); Model 2 adjusted for change in body weight in

addition to variables included in Model 1; Model 3 adjusted for change in VO_{2peak} in addition to

variables included in Model 1; Model 4 adjusted for change in rMSSD in addition to variables

included in Model 1. Abbreviations: CI: confidence interval; KKW: kilocalories of energy

expenditure per kilogram of body weight per week; OR: odds ratio; rMSSD: square root of the

mean of the sum of the squares of differences between adjacent R-R intervals; VO_{2peak}: peak rate

of oxygen consumption.




Figure 1. Participant screening and study flow. Of 4545 screened for participation, 464 postmenopausal women were randomised to one of four treatments. Baseline MOS Sleep data were available for 437 participants; those who discontinued the study or without follow-up MOS Sleep data had baseline data carried forward for analysis. BMI: body mass index; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

215x187mm (279 x 279 DPI)




Figure 2. Change in MOS Sleep Problems Index scores among treatment groups. Data presented as least-squares means \pm 95% confidence intervals. Analyses adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and baseline MOS SPI score. * Indicates difference from control ($P = .02$). KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study. 82x65mm (279 x 279 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Dose-Response Effects of Exercise Training on the Subjective Sleep Quality of Postmenopausal Women: ~~A~~Exploratory Analyses of a Randomised Controlled Trial

Christopher E. Kline,¹ Xuemei Sui,² Martica Hall,¹ Shawn D. Youngstedt,^{2,3,4}

Steven N. Blair,^{2,5} Conrad P. Earnest,⁶ Timothy S. ~~Church~~⁶Church⁷

¹ *Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA USA;*

² *Department of Exercise Science, University of South Carolina, Columbia, SC USA;*

³ *WJB Dorn VA Medical Center, Columbia, SC USA;*

⁴ *Department of Psychology, University of South Carolina, Columbia, SC USA;*

⁵ *Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC*

USA;

⁶ *Department for Health, University of Bath, Bath, UK;*

⁷ *Department of Preventive Medicine, Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA USA.*

Corresponding Author: Christopher E. Kline, Ph.D., Department of Psychiatry, University of

Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213; tel.: 412-578-

9554; fax: 412-246-5300; e-mail: klinec@upmc.edu.

Key words: exercise, sleep, postmenopausal, exercise training

Main text word count: 37293755

ABSTRACT

Objective: To investigate whether a dose-response relationship existed between exercise and subjective sleep quality in postmenopausal women. This objective represents a post-hoc assessment which was not previously considered.

Design: Parallel group randomised controlled trial.

Setting: Clinical exercise physiology laboratory in Dallas, Texas.

Participants: 437 sedentary overweight/obese postmenopausal women ~~with baseline sleep data (out of 464 enrolled for participation).~~

Intervention: Participants were randomised to 1 of 4 treatments, each of 6 months' duration: a non-exercise control treatment ($n=92$) or one of three dosages of moderate-intensity exercise (50% of VO_{2peak}), designed to meet 50% ($n=151$), 100% ($n=99$), or 150% ($n=95$) of NIH Consensus Development Panel physical activity recommendations. Exercise dosages were structured to elicit energy expenditures of 4, 8 or 12 kilocalories per kilogram of body weight per week (KKW), respectively. Analyses were intent-to-treat.

Primary outcome measures: Continuous scores and odds of having significant sleep disturbance, as assessed by the Sleep Problems Index from the 6-item Medical Outcomes Study (MOS) Sleep Scale. Outcome assessors were blinded to participant randomisation assignment.

Results: Change in the MOS Sleep Problems Index score significantly differed by treatment group (control: -2.09 [95% confidence interval, -4.58 to 0.40], 4 KKW: -3.93 [-5.87 to -1.99], 8 KKW: -4.06 [-6.45 to -1.67], 12 KKW: -6.22 [-8.68 to -3.77]; $P=.04$), with a significant dose-response trend observed ($P=.02$). Exercise training participants had lower odds of having significant sleep disturbance at post-intervention compared to control (4 KKW OR: 0.37 [0.19 to 0.73], 8 KKW: 0.36 [0.17 to 0.77], 12 KKW: 0.34 [0.16 to 0.72]). The magnitude of weight loss

1
2
3 did not differ between treatment conditions. Improvements in sleep quality were not related to
4
5 changes in body weight, resting parasympathetic control, or cardiorespiratory fitness.
6
7

8 **Conclusion:** Exercise training induced significant improvement in subjective sleep quality in
9
10 postmenopausal women, with even a low dose of exercise resulting in greatly reduced odds of
11
12 having significant sleep disturbance.
13

14
15 **Trial registration:** clinicaltrials.gov identifier: NCT00011193.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ARTICLE SUMMARY

Article Focus:

- Sleep disturbance is prevalent in postmenopausal women, with 35-60% reporting significant sleep problems.
- Effective, safe and easily available treatment options for disturbed sleep in postmenopausal women are lacking.
- There has been equivocal evidence as to whether exercise improves sleep in postmenopausal women, though possible dose-response effects have been noted.

Key Messages:

- Exercise resulted in significant improvement in subjective sleep quality in postmenopausal women, with reduced odds of having sleep disturbance at post-intervention with even 50% of the recommended dose of exercise for adults.
- The effects of exercise on sleep quality were independent of changes in body weight, resting parasympathetic control, or cardiorespiratory fitness.

Strengths and Limitations:

- The study constitutes the largest randomised controlled trial on exercise and sleep quality, using a structured dose of exercise and a validated measure of sleep quality.
- Only self-reported sleep was assessed; objective measurement of sleep, with either actigraphy or polysomnography, was not conducted.
- Despite the high prevalence of sleep disturbance in the sample, participants were not selected on the basis of sleep complaints.

INTRODUCTION

Disturbed sleep is a common complaint among women, with increasing prevalence beginning at the menopausal transition. Postmenopausal women are more likely to report sleep problems than premenopausal or perimenopausal women,[1] with 35-60% of postmenopausal women reporting significant sleep problems.[2] The first-line treatment options for sleep complaints, hypnotic medication and cognitive behavioral therapy, have associated concerns about the safety of long-term use or treatment availability, respectively.[3,4] Furthermore, results are conflicting on the effect of hormone replacement therapy (HRT) on sleep quality,[5,6] despite the effectiveness of HRT at reducing other menopausal symptoms.

A nonpharmacological treatment that has been traditionally thought to improve sleep is exercise. In epidemiologic research, exercise has frequently been associated with better sleep.[7] However, experimental research has provided less compelling evidence,[8] particularly when regarding postmenopausal women. Of the four randomised trials that have investigated the effect of exercise on sleep quality in this population,[9-12] only one reported a significant improvement in subjective sleep quality following an exercise intervention.[12] However, despite the generally negative findings from these studies involving postmenopausal women, possible dose-response effects of exercise on sleep quality were noted. In one of these studies, women who performed at least 225 minutes of morning exercise per week had less trouble falling asleep compared to those who exercised less than 180 minutes per week in the morning.[9] Likewise, another study reported a positive association between walking frequency and improvements in sleep.[11]

To our knowledge, no research has directly investigated the effects of different doses of exercise on sleep quality. The Dose-Response to Exercise in postmenopausal Women (DREW) trial was conducted to investigate the health effects of 50%, 100%, and 150% of the NIH

1
2
3 Consensus Development Panel physical activity recommendations in a group of sedentary
4
5 postmenopausal women.[13] Results on the primary outcomes of the study, cardiorespiratory
6
7 fitness and blood pressure, have already been reported.[14] Subjective sleep quality was also
8
9 assessed in this trial as an exploratory outcome, and the data provided herein provides the first
10
11 systematic examination of whether a dose-response relationship exists between exercise and
12
13 subjective sleep quality. It was hypothesised that, in comparison to a non-exercise control group,
14
15 subjective sleep quality would improve with increasing dosage of exercise.
16
17
18

19 20 METHODS

21
22 A complete description of the recruitment and screening procedures has been published
23
24 elsewhere.[13] Briefly, the study was a randomised, controlled, multi-arm parallel group trial in
25
26 which the primary outcomes were examining whether there were dose-response effects on
27
28 cardiorespiratory fitness and blood pressure with incrementally increasing doses of energy
29
30 expenditure.[13,14] The study was approved annually by the Cooper Institute Institutional
31
32 Review Board, and written informed consent was obtained by all participants prior to study
33
34 involvement.
35
36
37

38 39 Participants

40
41 Participants were recruited from the Dallas, Texas, metropolitan area from April 2001 to
42
43 June 2005. Of 4545 women screened for eligibility, those who were aged 45-75 years,
44
45 postmenopausal, sedentary (≤ 20 min of exercise on ≤ 2 days/week and < 8000 steps/day,
46
47 averaged over one week), overweight or obese (body mass index [BMI] of 25-43 kg/m²), and
48
49 had normal to mildly elevated resting blood pressure (systolic blood pressure [SBP] of 120-159
50
51 mm Hg and diastolic blood pressure [DBP] ≤ 99 mm Hg) were eligible to participate (Figure 1).
52
53
54
55 Exclusion criteria included significant cardiovascular disease, recent hospitalisation for mental
56
57
58
59
60

1
2
3 illness or significant symptoms of depression (score ≥ 10 on the Center for Epidemiologic
4
5 Studies Depression scale), or any other health condition that would contraindicate participation
6
7 in an exercise program. Overall, 464 women were randomised to treatment, with baseline sleep
8
9 data available for 437 participants.
10
11

12 **Randomisation and Retention**

14
15 Prior to randomisation, participants completed a two-week run-in period, in which
16
17 participants received lifestyle modification instruction over the course of six laboratory visits.
18
19 The primary purpose of this run-in period was to maximise retention and adherence to the
20
21 subsequent intervention. Participants were compensated for completing baseline and post-
22
23 intervention assessments, with additional compensation based on intervention adherence.[13]
24
25
26

27 Allocation of participants to treatment conditions was accomplished using a computer-
28
29 generated randomisation sequence, determined from randomly permuted blocks of equal length
30
31 with fixed numbers of treatment allotments to balance treatment enrollments over time.
32
33

34 Allocation concealment was achieved by placing treatment assignment letters into sequentially
35
36 numbered opaque envelopes sealed by the study statistician. At the time of randomisation,
37
38 envelopes were opened by a staff member not affiliated with the randomisation process.[13]
39
40

41 Participants were randomised to one of four treatment conditions: a non-exercise control
42
43 group, or one of three exercise groups expending 4, 8, or 12 kilocalories per kilogram of body
44
45 weight per week (KKW). Energy expenditure levels for the exercise groups were designed to
46
47 correspond with 50%, 100%, and 150% of the NIH Consensus Development Panel physical
48
49 activity recommendations, respectively.[15]
50
51

52 **Interventions**

53
54
55
56
57
58
59
60

1
2
3 Women assigned to the exercise groups participated in 3-4 training sessions/week for 6
4 months, alternating between semirecumbent cycle ergometer and treadmill exercise. Training
5 sessions were conducted in a supervised laboratory setting, and exercise dosage was closely
6 monitored for each session. Training intensity was moderate, set at the heart rate associated with
7 50% of each woman's VO_{2peak} and continuously monitored by heart rate telemetry. To determine
8 the number of calories that needed to be expended each week, participants were weighed weekly
9 and their weight was multiplied by the exercise dosage.
10
11
12
13
14
15
16
17
18

19 Exercise dose was gradually increased to minimise injury risk. All exercise training
20 groups expended 4 KKW during the first intervention week, with the 4-KKW group continuing
21 at that dose for 6 months. The 8- and 12-KKW groups increased their energy expenditure by 1
22 KKW until they reached their appointed exercise doses.
23
24
25
26
27
28

29 **Blinding**

30 Although participants could not be blinded to their treatment, staff were separated into
31 intervention and assessment teams to ensure blinding of all assessment staff to participant
32 randomisation assignment. Participants were consistently reminded to refrain from discussing
33 their randomisation assignments with outcome assessment staff.
34
35
36
37
38
39
40

41 **Sleep Measure**

42 Subjective sleep quality was assessed with six items from the Medical Outcomes Study
43 (MOS) Sleep Scale.[16] At baseline and post-intervention, participants were asked to respond
44 based on their sleep during the previous four weeks. One question, which addressed the length of
45 time to fall asleep, was framed with five response options ranging from 0-15 minutes to > 60
46 minutes. For the remaining five questions (i.e., restless sleep, daytime drowsiness, difficulty
47 falling asleep, awakening from sleep and experiencing difficulty returning to sleep, staying
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 awake during the day), participants were asked to respond on a 5-point scale, ranging from “none
4 of the time” to “all of the time”. Item responses were assigned scores using conventional scoring
5 rules, with higher scores indicating a greater severity of sleep disturbance. A modified Sleep
6 Problems Index (SPI), utilising all six sleep items, provided a measure of overall sleep
7 quality.[17] SPI scores greater than 25 were considered to indicate significant sleep disturbance,
8 as prior work utilising a 9-item SPI reported that a cutpoint of > 25 identified individuals who
9 considered themselves to have a sleep problem with a sensitivity of 86.2% and specificity of
10 66.3%.[17]

11
12 Scores on the MOS Sleep Scale have been shown to correlate with other MOS health
13 items,[16] differentiate between those with and without chronic health conditions,[17] and
14 improve with treatment of chronic health conditions.[18] Normative values for the general
15 population have also been developed.[17]

31 **Other Measures**

32
33 Baseline demographic and health characteristics were assessed by completion of a
34 comprehensive medical history questionnaire. Height and weight were measured with a
35 calibrated stadiometer and electronic scale, respectively. Diet was assessed before and following
36 the intervention using a semi-quantitative food frequency questionnaire, whereas unsupervised
37 physical activity was monitored throughout the study with a pedometer (Accusplit Eagle, Japan).

38
39 Cardiorespiratory fitness (VO_{2peak}) was assessed from maximal exercise testing using a
40 cycle ergometer (Excalibur Sport, Lode Medical Technology, Groningen, Netherlands), as
41 previously described.[14] Testing was performed twice at baseline and twice at post-
42 intervention, with values from each timepoint averaged. Heart rate variability (HRV) was
43 measured from the final 5 min of a 25-min resting assessment, as previously described.[19] The
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 square root of the mean of the sum of the squares of differences between adjacent R-R intervals
4
5 (rMSSD), a marker of parasympathetic activity,[20] was retained for analysis.
6
7

8 **Statistical Power**

9
10 Sample size was originally based on having adequate power to detect changes in the
11 primary outcomes of the overall study, VO_{2peak} and blood pressure.[14] Additional participants
12 were allocated to the 4 KKW condition to increase statistical power for detecting smaller
13 anticipated fitness gains in this group. Because sleep was not a primary outcome in the design of
14 the original study, there was no opportunity before data collection to investigate sample size or
15 power for this outcome variable. Nevertheless, given the current enrollment, the study had 84%
16 power (assuming two-tailed $\alpha = 0.05$) to detect an effect size of 0.20 for MOS SPI score
17 reduction.
18
19
20
21
22
23
24
25
26
27
28

29 **Statistical Analysis**

30
31 Baseline sleep quality was compared against normative data[17] using a one-sample *t*-
32 test. Continuous MOS SPI values were examined across quartiles of BMI, parasympathetic tone
33 (rMSSD), and cardiorespiratory fitness (VO_{2peak}) with analysis of covariance (ANCOVA),
34 controlling for age, BMI, sleep medication use, and HRT use. The likelihood of having
35 significant sleep disturbance at baseline (i.e., MOS SPI > 25) was evaluated with logistic
36 regression across the same quartiles using the same covariates.
37
38
39
40
41
42
43
44
45

46 Two primary outcomes were evaluated for the current study: (1) change in continuous
47 MOS SPI score across treatment groups; (2) odds of having significant sleep disturbance at post-
48 intervention across treatment groups. Change in continuous MOS SPI scores across groups was
49 tested by ANCOVA, with adjustment for age, BMI, sleep medication use, HRT use, and baseline
50 MOS SPI values. All assumptions underlying the ANCOVA models were checked and verified
51
52
53
54
55
56
57
58
59
60

1
2
3 | to be met. Individual treatment groups were compared to the control group with Tukey-Kramer
4
5 adjustment for multiple comparisons. An α level of .05 was used because it was our *a priori*
6
7 intention to compare only the separate treatment groups with the control group. Dose-response
8
9 trends were analysed using least-squares regression of MOS SPI change across groups. Logistic
10
11 regression examined the odds of having significant sleep disturbance at post-intervention,
12
13 following adjustment for age, BMI, sleep medication and HRT use, and baseline sleep
14
15 disturbance ($SPI > 25$, $SPI \leq 25$). Unadjusted analyses provided similar results to those with
16
17 covariate control, so only those results with full covariate adjustment were reported.
18
19

20
21
22 Finally, to examine whether improved sleep quality was significantly influenced by body
23
24 weight, parasympathetic tone, or cardiorespiratory fitness, changes in weight, rMSSD, and
25
26 VO_{2peak} were added to the ANCOVA and logistic regression analyses. Additionally, among
27
28 completed participants, changes in MOS SPI score were evaluated across quartiles of change in
29
30 body weight, rMSSD, and VO_{2peak} following adjustment for age, treatment, BMI, sleep
31
32 medication use, HRT use, and baseline MOS SPI score.
33
34

35
36
37 Analyses were limited to participants with baseline MOS Sleep data. Primary analyses
38
39 were conducted using the intent-to-treat principle; if post-intervention data were missing,
40
41 baseline values were carried forward for analysis. When analyses were restricted to only those
42
43 participants with baseline and post-intervention MOS Sleep data ($n = 359$), results were not
44
45 substantively changed; therefore similarly, when missing post-intervention data were imputed
46
47 with mean values, results were unchanged. Therefore, only intent-to-treat analyses were
48
49 presented. All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC). All
50
51 tests were two-tailed, with statistical significance set at $P \leq .05$.
52
53
54

55 RESULTS

56
57
58
59
60

Participant Characteristics

A summary of participant characteristics is provided in Table 1. Mean age and BMI of the 437 participants were 57.3 ± 6.5 yr and 31.8 ± 3.9 kg/m², respectively.

Baseline MOS SPI values and prevalence of sleep disturbance are provided in Table 1. Of the 437 participants, 46% of the sample ($n = 200$) were considered to have significant sleep disturbance at baseline, as defined as MOS SPI > 25. Baseline sleep quality of the participants was significantly worse than normative values[17] (normative value: 25.79; $t_{436} = 2.42$, $P = .02$), a magnitude of 0.12 SD.[21]

Baseline continuous MOS SPI values and odds of sleep disturbance across quartiles of BMI, rMSSD, and VO_{2peak} are shown in Table 2. Sleep quality significantly differed among quartiles of rMSSD ($F_{3,343} = 2.55$, $P = .05$), with the lowest quartile of rMSSD having significantly worse baseline sleep quality than the other quartiles of rMSSD. Similarly, each quartile of rMSSD was associated with lower odds of having significant sleep disturbance at baseline compared to the lowest quartile of rMSSD. No differences in MOS SPI values or odds of having significant sleep disturbance were observed across quartiles of BMI or VO_{2peak}.

Exercise Training Adherence, Diet and Unsupervised Activity

Treatment adherence was calculated as the percentage of exercise energy expenditure achieved compared to the amount of exercise energy expenditure that was prescribed. Adherence was similar between exercise groups (4 KKW: $95.1 \pm 16.1\%$, 8 KKW: $88.5 \pm 26.1\%$, 12 KKW: $92.5 \pm 20.9\%$), as previously reported.[14]

Changes in diet and unsupervised activity have been previously reported.[14,22] Pre- to post-intervention changes in energy intake did not differ between treatment conditions.

Pedometer-assessed unsupervised activity ranged from 4766 to 5067 steps/day at baseline and

1
2
3 did not differ between groups. Compared to baseline, daily steps increased for each group at
4 month 1 (each $P < .05$), with greater steps in the control group than the three exercise groups
5 (each $P < .05$). However, no differences in daily steps between the control and exercise groups
6 were observed by months 5 and 6. Among the exercise groups, daily steps did not change from
7 months 1 through 6. Therefore, the results reported here are unlikely to be due to changes in diet
8 or spontaneous activity outside the exercise training laboratory.
9

17 **Changes in Sleep Quality with Exercise Training**

19
20 Changes in sleep quality with exercise training are depicted in Figure 2. A significant
21 effect of the intervention was noted in the full model ($F_{8,428} = 17.35, P < .001$), with treatment
22 group being an independent predictor of change in continuous MOS SPI score ($F_{3,428} = 2.79, P =$
23 $.04$) following control for age, BMI, HRT use, sleep medication use, and baseline MOS SPI
24 values. Moreover, a significant linear dose-response effect was found for MOS SPI scores across
25 treatment groups ($P = .02$). When compared against control, a significantly greater improvement
26 in MOS SPI score was found for the 12-KKW group ($P = .02$).
27
28

29
30 The association between sleep disturbance (i.e., MOS SPI > 25) at post-intervention and
31 treatment is summarised in Table 3. Compared to control and following covariate adjustment,
32 each exercise training group had lower odds of having significant sleep disturbance following the
33 intervention, with the odds of having significant sleep disturbance decreasing while exercise
34 dose increased (linear trend $P = .01$).
35
36

48 **Influences of Change in Weight, Fitness, and Parasympathetic Tone on Sleep**

49
50 Post-intervention changes in body weight, parasympathetic tone, and cardiorespiratory
51 fitness for the overall DREW sample have been previously reported.[14,19] In the present
52 study's sample, the magnitude of weight loss did not differ between treatment groups (control: -
53
54
55
56
57
58
59
60

1
2
3 1.08 [3.70], 4 KKW: -1.23 [3.43], 8 KKW: -1.60 [3.23], 12 KKW: -1.25 [2.83] kg; $F_{3,433} = 0.43$,
4
5 $P = .73$). Cardiorespiratory fitness improved with exercise training in a dose-dependent manner
6
7 (control: -0.20 [1.88], 4 KKW: 0.59 [1.83], 8 KKW: 1.13 [1.54], 12 KKW: 1.42 [1.79]
8
9 mL/kg/min; $F_{3,433} = 15.32$, $P < .001$). Among those with usable HRV and sleep data ($n = 351$),
10
11 rMSSD improved in a dose-dependent fashion with exercise training (control: 0.20 [8.45], 4
12
13 KKW: 2.72 [9.20], 8 KKW: 3.72 [11.47], 12 KKW: 5.29 [9.51] ms; $F_{3,347} = 3.82$, $P = .01$).
14
15
16
17 When added to the model analysing differences in continuous MOS SPI change among treatment
18
19 groups, none of these covariates were significant ($P \leq .14$), and inclusion of these variables did
20
21 not alter the previously noted treatment group differences or linear dose-response effects. When
22
23 individually added to logistic regression analyses, none of these covariates significantly affected
24
25 the odds of having significant sleep disturbance at post-intervention (Table 3). In addition, when
26
27 change in MOS SPI was evaluated across quartiles of change in body weight, rMSSD, or
28
29 VO_{2peak} , no significant-between group differences were noted (data not shown). Finally, change
30
31 in MOS SPI did not correlate with change in body weight, rMSSD or VO_{2peak} ($r < .03$, $P > .58$).
32
33
34
35

36 DISCUSSION

37
38 The key finding from exploratory analyses of the DREW randomised controlled trial was
39
40 that exercise training significantly improved subjective sleep quality in overweight/obese
41
42 postmenopausal women. Specifically, we observed a dose-response trend for the continuous
43
44 MOS SPI values and, perhaps most notably, significantly reduced odds of having sleep
45
46 disturbance at post-intervention with even 50% of the recommended dose of exercise for adults.
47
48 Interestingly, the improvements in sleep quality were not related to changes in body weight,
49
50 parasympathetic tone, or cardiorespiratory fitness.
51
52
53
54

55 Previous research

1
2
3 Previous research with postmenopausal women had yielded conflicting findings
4 regarding whether exercise improved sleep.[9-12] While suggested by prior studies in this
5 population,[9,11] the present study is the first to document a dose-response relationship between
6 exercise and improved subjective sleep quality. Although sleep was an exploratory outcome of
7 the DREW study, it is the largest clinical trial to date that has examined the relationship between
8 aerobic exercise dose and sleep quality. Our current findings mirror the overall body of research
9 indicating that exercise improves sleep, most prominently in those with existing sleep
10 disturbances.[8]
11
12
13
14
15
16
17
18
19
20
21

22 **Clinical implications**

23
24 When considering the improvements in continuous MOS SPI scores following exercise
25 training, the clinical significance is uncertain. The observation that only those who exercised at a
26 12-KKW dose experienced a significant improvement in sleep quality compared to control may
27 be viewed as discouraging, as this dose equated to approximately 190 min/wk of moderate-
28 intensity aerobic exercise[14] and many individuals may not be willing to perform that much
29 exercise to improve sleep. However, the significant dose-response effect suggests that any dose
30 of exercise should benefit sleep, albeit with larger effects noted with higher levels of energy
31 expenditure.
32
33
34
35
36
37
38
39
40
41
42

43 In contrast, the greatly reduced odds of having significant sleep disturbance following
44 exercise training suggests that exercise may hold the most promise as a treatment option for
45 postmenopausal women with significant sleep disturbance. In particular, even an exercise dose
46 consisting of 50% of the NIH Consensus Panel physical activity recommendations significantly
47 reduced the odds of having a post-intervention MOS SPI > 25. This is noteworthy, since sleep
48 complaints are prevalent in postmenopausal women[1] and current treatment options, such as
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 HRT and hypnotic medication, have often been found to be only mildly efficacious at improving
4 sleep quality compared to placebo in postmenopausal women.[6,23]
5
6

7
8 The mechanisms by which exercise may improve subjective sleep quality in
9
10 postmenopausal women are unknown. Although the present study was not specifically designed
11 to address mechanisms of effect, secondary analyses focused on changes in three variables which
12 have been shown to be related to sleep: body weight, parasympathetic activity, and
13 cardiorespiratory fitness. There is a clear association between obesity and disturbed sleep,[24]
14 and weight loss has been found to reduce sleep complaints.[25] Likewise, poor sleepers have
15 been found to have impaired sleep HRV,[26] and exercise training has been well-documented to
16 improve autonomic function.[27] Finally, physical fitness has been previously associated with
17 sleep quality,[28] and greater improvements in fitness have been associated with better sleep
18 outcomes in some experimental studies.[9,12]
19
20
21
22
23
24
25
26
27
28
29
30

31
32 Nonetheless, in the present study, changes in body weight, parasympathetic tone, or
33 cardiorespiratory fitness were not significantly related to changes in sleep, whether assessed by
34 covariate control, change in sleep quality across quartiles of change in these variables, or
35 correlations between change in these variables and change in sleep quality. Although significant
36 improvements were noted for rMSSD and VO_{2peak} following exercise training in this
37 sample,[14,19] the variability associated with the sleep measure used in the current study may
38 have masked any possible associations. The present study suggests that exercise training can
39 result in improved sleep quality independent of weight loss, increased fitness, or improved
40 autonomic balance.
41
42
43
44
45
46
47
48
49
50
51

52 **Strengths and weaknesses**

53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths of the study include a randomised controlled design, closely supervised intervention, use of a validated measure of sleep quality, and the largest experimental sample size to investigate the effects of exercise on sleep. The study population was another strength, as the prevalence of disturbed sleep was high. Finally, assessment of variables that are related to sleep quality and may contribute to improved sleep following exercise training was another strength of the study.

A limitation of the study is that sleep quality was not a primary outcome of the original DREW trial. Therefore, results should be interpreted cautiously. Another study limitation is that sleep was not objectively assessed (i.e., via wrist actigraphy or polysomnography). Because of the subjective nature of the outcome and impossibility of blinding participants to their treatment, improvements in self-reported sleep quality may have been subject to expectancy effects, as exercise is commonly believed to improve sleep quality.[7] However, the finding of a significant linear trend between exercise dose and improvement in sleep quality would not necessarily be expected. Moreover, that sleep was not a primary outcome of interest and part of a wide range of study assessments further reduces the chance of expectancy or demand biases. Additionally, there is growing recognition of the merit of assessing subjective sleep quality.[29] For instance, in contrast with subjective sleep quality, objective sleep has not been found to be altered across the menopausal transition.[30] Furthermore, impaired subjective sleep quality is what prompts search for treatment, and recent evidence suggests that traditional objective sleep measures might be inadequate for detecting subtle indicators of disturbed sleep.[31] It is also noteworthy that subjective sleep quality has been associated with quality of life and physical and mental health in postmenopausal women.[32]

1
2
3 A lack of assessment of obstructive sleep apnoea (OSA) was another limitation. Although
4
5 OSA is considered to be a male-dominated sleep disorder, postmenopausal OSA prevalence is
6
7 similar between males and females.[33] Moreover, excess weight is the primary cause of OSA
8
9 for most adults,[34] which would place this overweight/obese sample at even higher risk for
10
11 OSA. Evidence suggests that exercise, in the absence of more established treatments or
12
13 significant weight loss, is moderately efficacious at reducing OSA severity and improving
14
15 sleep.[35] However, dose-response effects of exercise on OSA severity are unknown.
16
17
18

19
20 Finally, because aerobic activity was the only mode of exercise studied in the DREW
21
22 trial, the possible effects of resistance exercise on sleep quality could not be examined in this
23
24 sample. Resistance training has been shown to improve sleep quality,[36] though there has been
25
26 minimal work comparing different doses of resistance exercise on sleep quality.[37]
27
28

29 **Conclusions**

30
31 In summary, in a sample of overweight/obese postmenopausal women, exercise training
32
33 significantly reduced the odds of having significant sleep disturbance. These improvements in
34
35 sleep were independent of the effects of exercise training on body weight, parasympathetic tone,
36
37 or cardiorespiratory fitness. Additional research with more comprehensive measurement of sleep
38
39 is warranted, but exercise training appears to significantly improve sleep quality in
40
41 postmenopausal women.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ACKNOWLEDGMENTS

We thank the DREW participants and the Cooper Institute staff for their efforts on this study.

Contributors: TSC and SNB designed and organised the study. TSC, CPE, and SNB collected the data. CEK and XS performed the statistical analyses. CEK wrote the first draft of the manuscript. XS, MHH, SDY, CPE, SNB, and TSC provided critical input at all stages and critically reviewed and contributed to the final draft. CEK and TSC are guarantors.

Funding: This work was supported by grants HL66262 and T32 HL082610-05 from the National Institutes of Health, and American Heart Association Texas Affiliate award 02651404. Life Fitness (Schiller Park, Illinois) provided exercise equipment for this study.

Competing interest statement: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work (aside from the funding sources listed); no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Institutional Review Boards of the Cooper Institute (Dallas, TX) and the Pennington Biomedical Research Center (Baton Rouge, LA).

Role of the study sponsors: The sponsors had no role in the study design, protocol development, or in conducting the trial, data collection, data analysis, or preparation of the manuscript.

Data sharing: The data set will be available from the corresponding author as part of an academic collaboration.

Trial registration: Clinicaltrials.gov identification number NCT00011193.

REFERENCES

1. Kravitz HM, Ganz PA, Bromberger J, et al. Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition. *Menopause* 2003;10:19-28.
2. National Institutes of Health. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. *Ann Intern Med* 2005;142:1003-13.
3. Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. *J Gen Intern Med* 2007;22:1335-50.
4. Nowakowski S, Meliska CJ, Martinez LF, et al. Sleep and menopause. *Curr Neurol Neurosci Rep* 2009;9:165-72.
5. Sarti CD, Chiantera A, Graziottin A, et al. Hormone therapy and sleep quality in women around menopause. *Menopause* 2005;12:545-51.
6. Kalleinen N, Polo O, Himanen SL, et al. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. *Climacteric* 2008;11:233-43.
7. Youngstedt SD, Kline CE. Epidemiology of exercise and sleep. *Sleep Biol Rhythms* 2006;4:215-21.
8. Youngstedt SD. Effects of exercise on sleep. *Clin Sports Med* 2005;24:355-65.
9. Tworoger SS, Yasui Y, Vitiello MV, et al. Effects of a yearlong moderate-intensity exercise and a stretching intervention on sleep quality in postmenopausal women. *Sleep* 2003;26:830-6.
10. Elavsky S, McAuley E. Lack of perceived sleep improvement after 4-month structured exercise programs. *Menopause* 2007;14:535-40.

- 1
2
3 11. Wilbur J, Miller AM, McDevitt J, et al. Menopausal status, moderate-intensity walking, and
4 symptoms in midlife women. *Res Theory Nurs Pract* 2005;19:163-80.
5
6
- 7
8 12. King AC, Oman RF, Brassington GS, et al. Moderate-intensity exercise and self-rated
9 quality of sleep in older adults. A randomized controlled trial. *JAMA* 1997;277:32-7.
10
11
- 12 13. Morss GM, Jordan AN, Skinner JS, et al. Dose Response to Exercise in Women aged 45-75
13 yr (DREW): design and rationale. *Med Sci Sports Exerc* 2004;36:336-44.
14
15
- 16 14. Church TS, Earnest CP, Skinner JS, et al. Effects of different doses of physical activity on
17 cardiorespiratory fitness among sedentary, overweight or obese postmenopausal women
18 with elevated blood pressure: a randomized controlled trial. *JAMA* 2007;297:2081-91.
19
20
- 21 15. NIH Consensus Development Panel on Physical Activity and Cardiovascular Health.
22 Physical activity and cardiovascular health. *JAMA* 1996;276:241-6.
23
24
- 25 16. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, Jr., eds. *Measuring*
26 *Functioning and Well-being: The Medical Outcomes Study Approach*. Durham, NC: Duke
27 University Press 1992:235-59.
28
29
- 30 17. Hays RD, Martin SA, Sesti AM, et al. Psychometric properties of the Medical Outcomes
31 Study Sleep measure. *Sleep Med* 2005;6:41-4.
32
33
- 34 18. Allen RP, Kosinski M, Hill-Zabala CE, et al. Psychometric evaluation and tests of validity
35 of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). *Sleep Med* 2009;10:531-
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Earnest CP, Lavie CJ, Blair SN, et al. Heart rate variability characteristics in sedentary
postmenopausal women following six months of exercise training: the DREW study. *PLoS*
One 2008;3:e2288.

- 1
2
3 20. Task Force of the European Society of Cardiology and the North American Society of
4 Pacing and Electrophysiology. Heart rate variability: standards of measurement,
5 physiological interpretation, and clinical use. *Eur Heart J* 1996;17:354-81.
6
7
- 8
9 21. Cohen J. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Philadelphia, PA:
10 Lawrence Erlbaum Associates, Inc. 1988.
11
12
- 13 22. Church TS, Martin CK, Thompson AM, et al. Changes in weight, waist circumference and
14 compensatory responses with different doses of exercise among sedentary, overweight
15 postmenopausal women. *PLoS One* 2009;4:e4515.
16
17
- 18 23. Soares CN, Joffe H, Rubens R, et al. Eszopiclone in patients with insomnia during
19 perimenopause and early postmenopause: a randomized controlled trial. *Obstet Gynecol*
20 2006;108:1402-10.
21
22
- 23 24. Fogelholm M, Kronholm E, Kukkonen-Harjula K, et al. Sleep-related disturbances and
24 physical inactivity are independently associated with obesity in adults. *Int J Obes (Lond)*
25 2007;31:1713-21.
26
27
- 28 25. Dixon JB, Schachter LM, O'Brien PE. Sleep disturbance and obesity: changes following
29 surgically induced weight loss. *Arch Intern Med* 2001;161:102-6.
30
31
- 32 26. Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers.
33 *Psychosom Med*. 1998;60:610-5.
34
35
- 36 27. Routledge FS, Campbell TS, Fetridge-Durdle JA, et al. Improvements in heart rate
37 variability with exercise therapy. *Can J Cardiol* 2010;26:303-12.
38
39
- 40 28. Lee AJ, Lin WH. Association between sleep quality and physical fitness in female young
41 adults. *J Sports Med Phys Fitness* 2007;47:462-7.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 29. Buysse DJ, Reynolds CF III, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new
4 instrument for psychiatric practice and research. *Psychiatry Res* 1989;28:193-213.
5
6
7
- 8 30. Young T, Rabago D, Zgierska A, et al. Objective and subjective sleep quality in
9 premenopausal, perimenopausal, and postmenopausal women in the Wisconsin Sleep Cohort
10 Study. *Sleep* 2003;26:667-72.
11
12
13
- 14 31. Perlis ML, Smith MT, Andrews PJ, et al. Beta/Gamma EEG activity in patients with
15 primary and secondary insomnia and good sleeper controls. *Sleep* 2001;24:110-7.
16
17
18
- 19 32. Baker FC, Wolfson AR, Lee KA. Association of sociodemographic, lifestyle, and health
20 factors with sleep quality and daytime sleepiness in women: findings from the 2007 National
21 Sleep Foundation "Sleep in America Poll". *J Womens Health* 2009;18:841-9.
22
23
24
- 25 33. Young T, Finn L, Austin D, et al. Menopausal status and sleep-disordered breathing in the
26 Wisconsin Sleep Cohort Study. *Am J Respir Crit Care Med* 2003;167:1181-5.
27
28
29
- 30 34. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. *J Appl*
31 *Physiol* 2005;99:1592-9.
32
33
34
- 35 35. Kline CE, Crowley EP, Ewing GB, et al. The effect of exercise training on obstructive sleep
36 apnea and sleep quality: a randomized controlled trial. *Sleep* 2011;34:1631-40.
37
38
39
- 40 36. Singh NA, Clements KM, Fiatarone MA. A randomized controlled trial of the effect of
41 exercise on sleep. *Sleep* 1997;20:95-101.
42
43
44
- 45 37. Singh NA, Stavrinou TM, Scarbek Y, et al. A randomized controlled trial of high versus low
46 intensity weight training versus general practitioner care for clinical depression in older
47 adults. *J Gerontol A Biol Sci Med Sci* 2005;60:768-76.
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURE LEGENDS

Figure 1. *Participant screening and study flow.* Of 4545 screened for participation, 464 postmenopausal women were randomised to one of four treatments. Baseline MOS Sleep data were available for 437 participants; those who discontinued the study or without follow-up MOS Sleep data had baseline data carried forward for analysis. BMI: body mass index; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

Figure 2. *Change in MOS Sleep Problems Index scores among treatment groups.* Data presented as least-squares means \pm 95% confidence intervals. Analyses adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and baseline MOS SPI score. * Indicates difference from control ($P = .02$). KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study.

TABLES

Table 1. Baseline Participant Characteristics.

	All (N=437)	Control (n=92)	Exercise Groups		
			4 KKW (n=151)	8 KKW (n=99)	12 KKW (n=95)
Age, y	57.32 (6.46)	57.14 (5.91)	57.78 (6.53)	57.58 (6.63)	56.47 (6.72)
Education, y	14.03 (2.11)	14.01 (2.12)	13.80 (2.02)	14.37 (2.06)	14.00 (2.28)
Married, No. (%)	398 (91)	86 (93)	141 (94)	87 (88)	84 (88)
Ethnicity/race, No. (%)					
White	278 (64)	58 (63)	92 (61)	60 (61)	68 (72)
African-American	128 (29)	23 (25)	49 (32)	32 (32)	24 (25)
Hispanic/Other	31 (7)	11 (12)	10 (7)	7 (7)	3 (3)
Employed, No. (%)	304 (70)	62 (67)	105 (70)	67 (68)	70 (74)
Cigarette Smoking, No. (%)	25 (6)	5 (5)	8 (5)	4 (4)	8 (8)
Medication Use, No. (%)					
Antihypertensive	126 (29)	22 (24)	41 (27)	32 (32)	31 (33)
Hyperlipidemia	73 (17)	14 (15)	31 (21)	17 (17)	11 (12)
Thyroid	65 (15)	12 (13)	19 (13)	16 (16)	18 (19)
Antidepressant	78 (18)	16 (17)	28 (19)	18 (18)	16 (17)
HRT	202 (46)	48 (52)	67 (44)	43 (43)	44 (46)
Antianxiety	20 (5)	7 (8)	7 (5)	4 (4)	2 (2)
Sedatives/sleep aids	12 (3)	4 (4)	5 (3)	3 (3)	0 (0)
Energy Intake, kcal/d	2277.2 (952.6)	2277.4 (947.9)	2213.1 (941.6)	2290.7 (930.7)	2364.7 (1003.5)
Anthropometrics					
Weight, kg	84.46 (11.82)	85.77 (12.43)	83.56 (11.42)	84.74 (12.43)	84.33 (11.24)
Body mass index, kg/m ²	31.77 (3.85)	32.29 (3.94)	31.54 (3.80)	31.98 (4.08)	31.44 (3.58)
Cardiorespiratory Fitness					
Relative VO _{2peak} , mL/kg/min	15.37 (2.92)	15.56 (3.00)	15.44 (3.00)	14.70 (2.49)	15.77 (3.05)
Absolute VO _{2peak} , L/min	1.29 (0.26)	1.33 (0.28)	1.28 (0.24)	1.24 (0.24)	1.32 (0.26)
Heart Rate Variability [*]					
rMSSD, ms	22.83 (11.56)	23.35 (11.01)	23.58 (12.24)	23.25 (11.29)	20.68 (11.19)
Subjective Sleep Quality					
MOS Sleep Problems Index	27.92 (18.40)	28.37 (19.71)	27.03 (17.92)	27.35 (18.10)	29.47 (18.32)
Sleep disturbance, No. (%)	200 (46)	38 (41)	65 (43)	49 (49)	48 (51)

Data presented as mean (standard deviation) unless otherwise indicated. * Samples for rMSSD

data were 351, 79, 123, 73, and 76 participants for All, Control, 4 KKW, 8 KKW, and 12 KKW groups, respectively. Abbreviations: HRT: hormone replacement therapy; KKW: kilocalories of energy expenditure per kilogram of body weight per week; MOS: Medical Outcomes Study; rMSSD: square root of the mean of the sum of the squares of differences between adjacent R-R intervals; VO_{2peak}: peak rate of oxygen consumption.

Table 2. Associations Between Baseline Sleep Quality and BMI, Parasympathetic Tone, and Cardiorespiratory Fitness.

Variable	MOS SPI score (95% CI)	OR of MOS SPI > 25 (95% CI)
BMI (kg/m²)		
Q1: ≥ 34.7	27.95 (24.54, 31.36)	1.00 (referent)
Q2: 31.7 - < 34.7	24.37 (20.92, 27.82)	0.60 (0.35, 1.03)
Q3: 28.6 - < 31.7	30.48 (27.03, 33.94)	1.14 (0.67, 1.96)
Q4: < 28.6	28.85 (25.46, 32.24)	0.98 (0.58, 1.68)
Linear <i>P</i>	.26	.53
rMSSD (ms)		
Q1: < 15.0	31.77 (27.95, 35.59)	1.00 (referent)
Q2: 15.0 - < 20.9	24.77 (21.04, 28.51)*	0.53 (0.29, 0.97)
Q3: 20.9 - < 29.0	25.22 (21.36, 29.09)*	0.43 (0.23, 0.81)
Q4: ≥ 29.0	26.50 (22.64, 30.35)*	0.46 (0.25, 0.86)
Linear <i>P</i>	.08	.01
VO_{2peak} (mL/kg/min)		
Q1: < 13.4	29.55 (25.86, 33.25)	1.00 (referent)
Q2: 13.4 - < 15.2	28.80 (25.35, 32.25)	1.22 (0.70, 2.13)
Q3: 15.2 - < 17.0	28.60 (25.05, 32.15)	1.04 (0.58, 1.87)
Q4: ≥ 17.0	24.91 (21.41, 28.42)	0.63 (0.34, 1.14)
Linear <i>P</i>	.10	.09

Continuous baseline MOS SPI scores (left panels) and odds ratios of having significant sleep disturbance at baseline (MOS SPI > 25) (right panels) across quartiles of baseline BMI, rMSSD, and VO_{2peak}. All analyses adjusted for age, BMI, sleep medication use, and HRT use, except when the covariate quartile was the independent variable. * indicates significant difference ($P \leq .05$) in MOS SPI score compared to quartile 1 (referent group). Abbreviations: BMI: body mass index; CI: confidence interval; MOS: Medical Outcomes Study; Q: quartile; rMSSD: square root of the mean of the sum of the squares of differences between adjacent R-R intervals; SPI: Sleep Problems Index; VO_{2peak}: peak rate of oxygen consumption.

Table 3. Prevalence and Odds of Significant Sleep Disturbance (i.e., MOS SPI > 25) at Post-Intervention.

	Prevalence	Model 1	Model 2	Model 3	Model 4
	<i>n</i> (%)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
Control	41 (45%)	1.00 (referent)	1.00 (referent)	1.00 (referent)	1.00 (referent)
4 KKW	46 (31%)	0.37 (0.19, 0.73)	0.37 (0.19, 0.73)	0.34 (0.19, 0.73)	0.37 (0.19, 0.73)
8 KKW	33 (33%)	0.36 (0.17, 0.77)	0.36 (0.17, 0.77)	0.32 (0.17, 0.77)	0.36 (0.17, 0.77)
12 KKW	31 (33%)	0.34 (0.16, 0.72)	0.34 (0.16, 0.72)	0.28 (0.16, 0.72)	0.34 (0.16, 0.72)
Linear trend <i>P</i>		.01	.01	.006	.02
Weight change		---	1.00 (0.93, 1.08)	---	---
VO _{2peak} change		---	---	1.10 (0.95, 1.26)	---
rMSSD change		---	---	---	1.01 (0.98, 1.04)

Model 1 adjusted for age, BMI, sleep medication use, hormone replacement therapy use, and

baseline sleep quality (SPI ≤ 25, SPI > 25); Model 2 adjusted for change in body weight in

addition to variables included in Model 1; Model 3 adjusted for change in VO_{2peak} in addition to

variables included in Model 1; Model 4 adjusted for change in rMSSD in addition to variables

included in Model 1. Abbreviations: CI: confidence interval; KKW: kilocalories of energy

expenditure per kilogram of body weight per week; OR: odds ratio; rMSSD: square root of the

mean of the sum of the squares of differences between adjacent R-R intervals; VO_{2peak}: peak rate

of oxygen consumption.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49



CONSORT 2010 checklist of information to include when reporting a randomised trial*

Section/Topic	Item No	Checklist item	Reported on page No
Title and abstract			
	1a	Identification as a randomised trial in the title	p.1
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	pp. 2-3
Introduction			
Background and objectives	2a	Scientific background and explanation of rationale	pp. 5-6
	2b	Specific objectives or hypotheses	p. 6
Methods			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	p. 6, p. 10
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	pp. 6-7
	4b	Settings and locations where the data were collected	p. 6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	pp. 7-8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	pp. 8-10
	6b	Any changes to trial outcomes after the trial commenced, with reasons	NA
Sample size	7a	How sample size was determined	p. 10
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
Randomisation:			
Sequence generation	8a	Method used to generate the random allocation sequence	p. 7
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	p. 7
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	p. 7
Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	p. 7
Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those	p. 8

1			
2		assessing outcomes) and how	
3			
4		11b If relevant, description of the similarity of interventions	p. 7
5	Statistical methods	12a Statistical methods used to compare groups for primary and secondary outcomes	pp. 10-11
6		12b Methods for additional analyses, such as subgroup analyses and adjusted analyses	pp. 10-11
7			
8	Results		
9	Participant flow (a	13a For each group, the numbers of participants who were randomly assigned, received intended treatment,	
10	diagram is strongly	and were analysed for the primary outcome	p. 12; Fig. 1
11	recommended)	13b For each group, losses and exclusions after randomisation, together with reasons	Fig. 1
12	Recruitment	14a Dates defining the periods of recruitment and follow-up	p. 6
13		14b Why the trial ended or was stopped	NA
14			
15	Baseline data	15 A table showing baseline demographic and clinical characteristics for each group	p. 12, Table 1
16	Numbers analysed	16 For each group, number of participants (denominator) included in each analysis and whether the analysis	
17		was by original assigned groups	p.11, Fig. 1
18			
19	Outcomes and	17a For each primary and secondary outcome, results for each group, and the estimated effect size and its	p. 13, Fig. 2, Table
20	estimation	precision (such as 95% confidence interval)	3
21		17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended	p. 13, Table 3
22	Ancillary analyses	18 Results of any other analyses performed, including subgroup analyses and adjusted analyses,	
23		distinguishing pre-specified from exploratory	pp. 13-14
24			
25	Harms	19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA
26			
27	Discussion		
28	Limitations	20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	pp. 16-18
29	Generalisability	21 Generalisability (external validity, applicability) of the trial findings	p. 15, pp. 17-18
30	Interpretation	22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	pp. 14-15
31			
32	Other information		
33	Registration	23 Registration number and name of trial registry	p. 3, p. 20
34	Protocol	24 Where the full trial protocol can be accessed, if available	p. 6, Ref. 13
35	Funding	25 Sources of funding and other support (such as supply of drugs), role of funders	pp. 19-20
36			

*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.